

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

COVID-19 and Perinatal Intimate Partner Violence: A cross-sectional survey of pregnant and post-partum individuals in the early stages of the COVID-19 pandemic

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-049295
Article Type:	Original research
Date Submitted by the Author:	21-Jan-2021
Complete List of Authors:	Muldoon, K; Ottawa Hospital Research Institute; University of Ottawa, Obstetrics and Gynecology Denize, Kathryn; Ottawa Hospital Research Institute Talarico, Robert; Ottawa Hospital Research Institute Boisvert, Carlie; Ottawa Hospital Research Institute; University of Ottawa, Faculty of Medicine Frank, Olivia; Ottawa Hospital Research Institute; Columbia University, Mailman School of Public Health Harvey, Alysha; Ottawa Hospital Research Institute White, Ruth; Ottawa Hospital Research Institute Fell, DB; University of Ottawa, School of Epidemiology and Public Health; Children's Hospital of Eastern Ontario Research Institute O'Hare-Gordon, Meagan Ann; Ottawa Hospital Research Institute Guo, Yanfang; Children's Hospital of Eastern Ontario, BORN Ontario; University of Ottawa, School of Epidemiology and Public Health Murphy, Malia; Ottawa Hospital Research Institute, Clinical Epidemiology Program Corsi, Daniel J.; Ottawa Hospital Research Institute; Children's Hospital of Eastern Ontario Research Institute Sampsel, Kari; University of Ottawa, Emergency Medicine; Ottawa Hospital Research Institute Wen, Shi Wu; Ottawa Hospital Research Institute; University of Ottawa, School of Epidemiology and Public Health Walker, Mark; Ottawa Hospital Research Institute, Clinical Epidemiology Program; University of Ottawa, Obstetrics and Gynecology El-Chaar, Darine; Ottawa Hospital Research Institute, Clinical Epidemiology Program; University of Ottawa, Faculty of Medicine
Keywords:	COVID-19, OBSTETRICS, Maternal medicine < OBSTETRICS, PUBLIC HEALTH, SOCIAL MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

*COVID-19 and perinatal IPV***COVID-19 and Perinatal Intimate Partner Violence: A cross-sectional survey of pregnant and post-partum individuals in the early stages of the COVID-19 pandemic**

Katherine A. Muldoon, PhD¹, Kathryn M. Denize, MSc¹, Robert Talarico, MSc¹, Carlie Boisvert,² Olivia Frank,¹ Alysha LJ Harvey, MSc¹, Ruth Rennicks White, RN¹, Deshayne B. Fell^{3,4}, PhD., Meagan Ann O'Hare Gordon,¹ Yanfang Guo,^{1,3,4} Malia SQ Murphy,¹ Daniel Corsi,^{1,3,4} Kari Sampsel MD,^{1,2} Shi Wu Wen, PhD,^{1,3} Mark Walker, MD,^{1,2,3} Darine El-Chaâr, MD^{1,2}

1. Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
2. Faculty of Medicine, The Ottawa Hospital and University of Ottawa, Ottawa, Ontario, Canada
3. School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario
4. Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario

Send correspondence to: Dr. Katherine Muldoon
Senior Research Associate, Ottawa Hospital Research Institute
501 Smyth Road
Ottawa, Ontario
K1H-8L6
Email: kmuldoon@ohri.ca
Telephone: 613-737-8899 x 77235

Manuscript word count: 3449 (3500 max)

Abstract word count: 344 (350 max)

Key words: intimate partner violence, perinatal IPV, COVID-19, violence, abuse, perinatal health

*COVID-19 and perinatal IPV***Abstract**

Objective: This study was designed to investigate the prevalence, patterns and risk factors for perinatal IPV among those who gave birth since COVID-19 began

Design: Cross-sectional survey

Setting: The Ottawa Hospital, Department of Obstetrics and Gynecology, Ottawa, Ontario

Participants: Patients who gave birth at TOH and were >20 days post-partum between March 17th-June 16th 2020.

Main outcomes and measures: Perinatal IPV was defined as psychological abuse, physical abuse, and/or sexual abuse in the 12 months before pregnancy, during pregnancy and/or post-partum. Log-binomial multivariable regression models were used to compute adjusted risk ratios (aRR) and 95% confidence intervals (CI) to quantify relationships with potential risk factors for IPV: maternal age, parity, household income, post-partum depression, and increase in partner substance use.

Results: Among 216 participants, the median maternal age was 33 years (interquartile range (IQR): 30-36). In total, 52 (24.1%) reported some form of IPV - 37 (17.1%) reported controlling partners; 13 (6.0%) reported abuse in the 12 months before pregnancy, 11 (5.1%) during pregnancy, and 15 (6.9%) during post-partum. Household income below the municipal median was the strongest risk factor for any IPV (aRR: 3.24, 95% CI: 1.87-5.59). There was no apparent association between maternal age (aRR: 0.99, 95% CI: 0.94-1.04), nulliparity (aRR: 1.18, 95% CI: 0.71-1.97), post-partum depression (aRR: 1.03, 95% CI: 1.00-1.07), or partner substance use increase since COVID-19 began (aRR: 0.73, 95% CI: 0.42-1.25) with IPV.

Conclusion: 1 in 4 individuals in this study experienced perinatal IPV since COVID-19 began. Household income was the strongest risk factor for perinatal IPV, and surprisingly, many hypothesized risk factors (e.g., mental health, increased partner substance use etc.) were not significantly associated with perinatal IPV in this sample. This highlights the challenges in both measuring IPV and identifying individuals exposed to perinatal IPV during the high stress of the COVID-19 pandemic.

Abstract word count: 300 (300 max)

Key words: intimate partner violence, perinatal IPV, COVID-19-19, violence, abuse, perinatal health

*COVID-19 and perinatal IPV***Strengths and Limitations**

- This study uses a detailed definition of IPV including emotional, psychological, physical and sexual violence during pre-pregnancy, prenatal and post-partum periods
- There is detailed information on household stressors and changes directly attributable to the COVID-19 pandemic protocols
- There is detailed information on race, socio-economic status, and partner characteristics
- Self-selection into the survey is a source of selection bias and under-reporting of IPV is a source of measurement bias
- This study does not have a comparison group of participants prior to COVID-19 and is unable to estimate changes in IPV attributable to the stress of the COVID-19 pandemic.

Funding

This work was supported by The Ottawa Hospital Academic Medical Organization (TOHAMO): TOH-20-005.

Competing interests

All authors declare no conflicts of interest

COVID-19 and perinatal IPV

18

19 Introduction

20 The evolving COVID-19 pandemic continues to cause extreme stress, unease and fear, all factors
21 that can increase the risk of intimate partner violence (IPV).¹⁻⁵ IPV broadly encompasses any
22 form of emotional abuse, threatening behaviour, psychological harm, physical violence or sexual
23 violence from a current or former intimate partner or spouse.⁶ Shortly after the initial declaration
24 of COVID-19 as a global pandemic on March 11th 2020, the United Nations released a statement
25 on March 27th 2020 warning of increased risks of IPV,⁷ in addition to the health-related
26 consequences of COVID-19 infection.⁸⁻¹⁰ It is estimated that over 30% of women have
27 experienced IPV in their lives¹¹ and 3-9% of individuals experience perinatal IPV, defined as
28 violence or abuse that occurs 12 months prior to pregnancy, during pregnancy and up to one year
29 post-partum.¹² To date, there is currently limited data on the prevalence and risk factors of
30 perinatal IPV during the COVID-19 pandemic, despite the rising global concern for both
31 pregnant people and the increase in violence.

32

33 The primary sources of data on violence during the COVID-19 pandemic have come from
34 emergency departments (ED), policing or crime data, and online surveys. Most EDs saw drastic
35 decreases in all-cause admissions immediately following the COVID-19 lockdown.^{13,14}
36 Investigations of cause-specific ED admissions varied, where some studies identified increases
37 in IPV or assault-based cases^{15,16} while others reported decreases.^{17,18} Mixed patterns have also
38 been observed in crime data from police departments, where some settings reported increases in
39 domestic violence cases,¹⁹⁻²¹ some found decreases,^{22,23} and others identified no detectable
40 changes.^{24,25} An online survey of over 2000 cis-gendered women from the United States found

COVID-19 and perinatal IPV

1
2
3 41 that 16% had experienced IPV since the beginning of 2020, including 11% being emotionally
4
5 42 abused, 5% forced to engage in unwanted sexual activity, and 6% physically harmed.²⁶ Another
6
7 43 survey of over 2400 Americans found that 18% had a history of IPV, and of those, 17% reported
8
9 44 that IPV had gotten worse since COVID-19 began.²⁷ A representative sample of over 2000 adults
10
11 45 in New Zealand experienced some form of sexual, physical or emotional abuse during the first
12
13 46 month of the COVID-19 pandemic.²⁸ Collectively, these studies highlight the complexities of
14
15 47 assessing and evaluating patterns of violence and IPV during the pandemic, however none have
16
17 48 included information on pregnancy or post-partum status, thus limiting our understanding of
18
19 49 perinatal IPV during COVID-19.
20
21
22
23
24
25

26 51 There is a growing body of evidence on the adverse maternal and infant outcomes associated
27
28 52 with COVID-19 infection, including higher risk of pre-term birth, cesarean birth, and some cases
29
30 53 of fetal and maternal death.^{29–35} A recent US Centers for Disease Control surveillance report
31
32 54 of 24,434 pregnant individuals with COVID-19 infection identified higher risk of admission to
33
34 55 intensive care, invasive ventilation, and death compared to non-pregnant individuals of
35
36 56 reproductive age.³⁶ A systematic review of maternal mental health during COVID-19 found
37
38 57 significant increases in risk of anxiety and higher scores on the Edinburgh Postnatal Depression
39
40 58 Survey (EPDS) among pregnant and post-partum individuals during COVID-19 compared to
41
42 59 pre-COVID-19.³⁷ A new scale, called the Pandemic Related Pregnancy Stress (PREPS) scale
43
44 60 was developed and found that a history of abuse was an independent predictor of moderate or
45
46 61 severe anxiety during COVID-19.³⁸ To our knowledge, this is the only study that captured
47
48 62 information on historical abuse among a perinatal sample, however there was no information on
49
50 63 perinatal IPV.
51
52
53
54
55
56
57
58
59
60

COVID-19 and perinatal IPV

1
2
3 64
4
5 65
6
7
8 66 Given the limited evidence base on perinatal IPV during COVID-19 and growing concern about
9
10 67 maternal health and safety, the goal of this study was to investigate perinatal IPV among those
11
12 68 who gave birth during the COVID-19 pandemic. The specific objectives were to: 1) document
13
14 69 violent and abusive behaviours within intimate partnerships during the perinatal period; and 2)
15
16 70 determine the household, interpersonal, and individual-level factors influencing the risk of
17
18
19 71 perinatal IPV.
20
21
22 72

Methods*Study setting and context*

23
24
25
26 74
27
28 75 This study took place in Ottawa, Ontario, the fourth largest city in Canada with a census
29
30 76 metropolitan population of 1.3 million. At the time of the study, the cumulative number of
31
32 77 confirmed COVID-19 cases in Ottawa was 2 650 (40 161 cases in the province of Ontario, and
33
34 78 119 451 cases in Canada.³⁹ The provincial government declared a state of emergency on March
35
36 79 17, 2020 to reduce the spread of COVID-19 infection. As a result, most public establishments
37
38 80 were closed (e.g., schools, childcare centers, libraries, recreational centers, restaurants, theatres
39
40 81 and concert venues etc.) and most workplaces transitioned to remote work.
41
42
43
44
45 82

46
47 83 This study was conducted at The Ottawa Hospital, a multi-site tertiary-care facility with two
48
49 84 obstetrical wards across the city. In response to the pandemic, the Department of Obstetrics,
50
51 85 Gynaecology and Newborn Care implemented safety protocols whereby all pregnant patients
52
53 86 underwent symptomatic screening for COVID-19 at the hospital entrance and again upon entry
54
55
56
57
58
59
60

COVID-19 and perinatal IPV

1
2
3 87 to the Maternal and Newborn Care floor. Care providers wore full personal protective equipment
4
5 88 at all times (e.g. universal masking) as part of the hospital wide policy. A partner or support
6
7
8 89 person could only enter once (i.e., no in and out privileges) after screening negative for COVID-
9
10 90 19. However, partners were not able to attend caesarean births in the operating room. After birth,
11
12 91 patients were not allowed to leave their hospital room for any reason and no additional children
13
14 92 or family members were allowed to visit. For infants admitted to the Neonatal Intensive Care
15
16 93 Unit (NICU), only one parent could be present at a time.
17
18
19 94

Study design and recruitment

20
21 95
22
23 96 This is a cross-sectional survey of patients who gave birth at The Ottawa Hospital who were
24
25 97 between 20-90 days post-partum. Patients were identified through the hospital birth records and
26
27 98 contacted for a one-time survey if they had given birth after 17th March 2020, were 16 years of
28
29 99 age or older, and consented to the hospital's Permission to Contact Program. Patients were
30
31 100 contacted by phone and after they had provided verbal informed consent, a link to the survey was
32
33 101 sent to their email address. The survey took 10 minutes to complete and was designed to estimate
34
35 102 the prevalence of perinatal IPV and capture information on prenatal care, labour and delivery,
36
37 103 and post-partum experiences during the COVID-19 pandemic that may influence the risk of IPV.
38
39 104 All participants were provided with links to community resources or encouraged to contact the
40
41 105 hospital for referrals.
42
43
44
45
46
47
48

Patient and Public Involvement

49 107
50
51 108 The survey and all study materials were developed in collaboration with a Patient Partner
52
53 109 (O'Hare-Gordon), who was admitted to hospital during the COVID-19 pandemic and unable to
54
55
56
57
58
59
60

COVID-19 and perinatal IPV

1
2
3 110 see her partner and children for 5 weeks (22nd April to 27th May, 2020). She gave birth to pre-
4
5 111 term twins who were admitted to the Neonatal Intensive Care Unit (NICU) for 19 days.⁴⁰ Her
6
7 112 first-hand experience is invaluable to understanding the patient perspective and ensuring that the
8
9 113 resources, study materials, and findings are relevant to the perinatal population. The Patient
10
11 114 Partner was not involved in recruitment. Participants will not be directly contacted with the
12
13 115 results of the study because of the sensitive nature of the project, however, public dissemination
14
15 116 of the findings are available through the institutional online platforms.
16
17
18
19 117

Outcomes

20
21
22 118
23
24 119 Perinatal IPV was measured by two scales from the World Health Organization multi-country
25
26 120 study on domestic violence.⁴¹ Scale One, comprised of eight questions, measures different forms
27
28 121 of controlling behaviour regularly exhibited by the partner (e.g., insists on knowing where you
29
30 122 are at all times, restricting from connecting with friends or family, is suspicious of infidelity,
31
32 123 etc.). Scale Two, measures specific acts of IPV. Four items measured emotional or psychological
33
34 124 abuse (i.e., insulting, belittling, intimidating, threatening to hurt someone you care about), six
35
36 125 items measured physical abuse (i.e., slapped, pushed, hit, strangled, threatened with a weapon),
37
38 126 and three items measured sexual abuse (i.e., forced to have unwanted sexual intercourse, forced
39
40 127 to have other unwanted sexual activities, forced to engage in unwanted sexual activities they
41
42 128 considered degrading or humiliating). Participants were asked if they experienced
43
44 129 emotional/psychological, physical and sexual abuse during each of the following perinatal time
45
46 130 periods: 12 months before pregnancy, during pregnancy, and post-partum. A composite outcome
47
48 131 of any perinatal IPV was defined as experiencing any form of regular controlling behaviour
49
50 132 (Scale One) or emotional/psychological, physical, or sexual abuse (Scale Two).
51
52
53
54
55
56
57
58
59
60

COVID-19 and perinatal IPV

1
2
3 133
4
5 134 *Covariables*
6
7
8 135 Demographic characteristics included age of mother (in years) and age of infant (in days) at the
9
10 136 time of the survey Maternal race or ethnicity was measured using the Ottawa Public Health
11
12 137 questions on race and ethnicity developed with community members, which allows multiple
13
14 138 categories.⁴² The following ethnicities are presented White, Asian (including South, South-East,
15
16 139 East), Middle Eastern, Black, and Another Person of Colour (POC)). Participants were asked if
17
18 140 they were born in Canada or had immigrated from another country. Participants were asked to
19
20 141 identify any languages they feel comfortable speaking (i.e. English, French, or another
21
22 142 language). Marital status compared those who were married/common law versus single/another
23
24 143 status. Education level was measured as completing a college diploma or undergraduate
25
26 144 university degree or higher. Participants reported if they owned their dwelling (versus rented)
27
28 145 and their combined household income (before taxes), which was dichotomized as either at or
29
30 146 below the median total household income for the Ottawa region (119 440 CAD) as determined
31
32 147 by the Canadian Census.⁴³
33
34
35
36
37 148
38
39
40 149 COVID-19 related household stress was measured by loss of income due to COVID-19 protocols
41
42 150 (i.e. permanent job loss, temporarily laid off, or reduced hours). We asked the participants if their
43
44 151 partners were essential workers, defined as those who were required to continue working during
45
46 152 lockdown to maintain the city infrastructure. Participants were asked if their partner had
47
48 153 increased substance use since COVID-19 began (i.e. alcohol, cannabis, tobacco, another
49
50 154 substance). Changes to childcare were measured as children stopped going to school or daycare,
51
52
53
54 155 no changes to childcare, or no children.
55
56
57
58
59
60

COVID-19 and perinatal IPV

1
2
3 156
4
5 157 Maternal experiences of COVID-19-related isolation included not being able to have a baby
6
7
8 158 shower (or other planned celebration), a family member could not come and stay with them as
9
10 159 planned, friends and family could not visit the new infant, or they missed out on community
11
12 160 resources (e.g. mom-baby groups, breastfeeding support groups, play dates).
13

14 161
15
16 162 Measures of maternal mental health include pre-existing anxiety, pre-existing depression,
17
18 163 defined as receiving any counseling or treatment for anxiety or depression. Postpartum
19
20 164 depression was measured using the Edinburgh Postnatal Depression Scale (EPDS). The EPDS is
21
22 165 the most reliable and widely used screening tool for postpartum depression. The 10-item scale
23
24 166 ranges from 0 to 30 and a score of 13 or greater on the EPDS indicates a high likelihood of
25
26 167 depression and further assessment/management is needed. The score was presented continuously
27
28 168 and dichotomized at 13 or greater to indicate post-partum depression. If a participant scored
29
30 169 greater than 13 or indicated risk of suicidality (item 10), the Principal Investigator (DE,
31
32 170 Obstetrician) was notified within 24 hours of survey completion for a chart review and clinical
33
34 171 follow-up.
35
36
37
38
39

40 172
41
42 173 Participants reported on their in-hospital care experience including if they had to wear a mask
43
44 174 during delivery and if they were alone for the whole admission (including early labour, active
45
46 175 labour/delivery, and post-partum) without a support person. Participants were asked if they had
47
48 176 any post-partum visit to an emergency department for mother or infant.
49
50

51 177
52
53
54
55
56
57
58
59
60

COVID-19 and perinatal IPV

1
2
3 178 A series of questions were asked around coping mechanisms to deal with the stress of COVID-
4
5 179 19 pandemic, which were then dichotomized as positive coping strategies (e.g. yoga, exercising,
6
7
8 180 donating to charities, connecting with friends/family) and negative coping strategies (e.g.
9
10 181 sleeping more/less than usual; over/under eating, acting aggressively).
11
12
13 182

Analyses

14
15 183
16
17 184 All analyses were conducted using SAS 9.4.⁴⁴ In accordance with privacy guidelines, all cell
18
19 185 sizes ≤ 5 were suppressed to ensure non-identification. The characteristics of the sample were
20
21
22 186 summarized using descriptive statistics include frequencies and percentages for categorical
23
24 187 variables. Continuous variables were summarized using median and interquartile range (IQR).
25
26 188 The characteristics of the sample were compared between those who had experienced IPV versus
27
28 189 those who had not by calculating Chi-square tests for categorical variables and Wilcoxon ranked
29
30
31 190 sum test for continuous variables.
32

33 191
34
35 192 Log binomial regression models were calculated to investigate the association between five pre-
36
37 193 specified risk factors and perinatal IPV using unadjusted Risk Ratios (RR) and 95% confidence
38
39 194 intervals (CI). The selected factors included maternal age, parity, household income below the
40
41
42 195 median, EPDS Score, and increase in partner substance use. All covariables of interest were
43
44 196 included in the multivariable model and presented using adjusted RR and 95% CI.
45
46

47 197
48
49 198 Seven participants had at least one missing EPDS component. To compute the EPDS score we
50
51 199 imputed missing components with the mean of the participant's non-missing components. In the
52
53
54
55
56
57
58
59
60

COVID-19 and perinatal IPV

200 multivariable model, missing data for household income was imputed by multiple imputation
201 using chained equations and models were averaged across 10 imputed datasets.⁴⁵

202

203 *Ethics*

204 This study was approved by the Ottawa Health Sciences Network Research Ethics Board
205 (Protocol number: 20170390-01H).

206

207

208 **Results**

209 Between March 17th and June 16th, 1568 individuals gave birth at The Ottawa Hospital. Of those,
210 613 agreed to be contacted for research, 572 had valid phone numbers and were contacted, 302
211 consented to the study, and 261 completed the survey, for a response rate of 42.58%. After
212 excluding those who did not finish the survey, the final analytical sample was of 216 participants
213 (35.2% of those who agreed to be contacted). No participants in the study reported current or
214 previous COVID-19 infection.

215

216 In total there were 52 (24.07%) participants who reported some form of perinatal IPV or
217 controlling behaviour from a partner. In total, 37 (17.13%) reported that their partners regularly
218 exhibited controlling behavior. The most common controlling behaviours were insisting on
219 knowing where you are at all times (8.37%), try to keep you from seeing your friends (5.58%)
220 and get angry if you speak with another man/person they would feel jealous of (4.65%) (Figure
221 1).

222

COVID-19 and perinatal IPV

223 Figure 2 displays the frequency of the specific forms of perinatal IPV experienced by
224 participants during each window of the perinatal period. In total, 13 (6.05%) experienced any
225 form of IPV during the 12 months prior to pregnancy, 11 (5.12%) during pregnancy, and 15
226 (6.98%) during post-partum. The most common form of IPV reported by participants across all
227 time periods was emotional abuse (10.23%). Sexual abuse was reported by 2.33% of
228 participants, and less than 1% reported any physical abuse.

230 The demographic characteristics of the sample are presented in Table 1. The maternal median
231 age was 33 years (IQR:30-36) and the infant median age at the time of the survey was 76 days
232 (IQR:66-90). The sample was diverse with 147 (68.06%) identifying as White, 31 (14.35%)
233 South/South-East or East Asian, 18 (8.33%) Middle Eastern, 17 (7.87%) Black, and 25 (11.57%)
234 identifying with another race or ethnic group. There were 151 (69.91%) participants who owned
235 their homes and 80 (37.04%) had household incomes below the municipal median.

237 Owing to COVID-19 restrictions, 64 (29.63%) reported household income loss, 55 (25.46%)
238 reported their partner was an essential worker who continued to work on the front line. There
239 were 45 (20.83%) participants who reported that their partner had increased substance use since
240 COVID-19 began. Regarding maternal mental health, 43 (19.91%) had pre-existing anxiety and
241 29 (13.43%) had pre-existing depression. There were 64 (29.63%) participants flagged for post-
242 partum depression through the EPDS.

244 The bivariable and multivariable log-binomial regression models are presented in Table 2. At the
245 bivariable level, household income below the municipal median (RR: 3.66, 95% CI:2.07-6.48) was

COVID-19 and perinatal IPV

1
2
3 246 significantly associated with perinatal IPV and EPDS score (RR:1.04, 1.00-1.10) was marginally
4
5 247 associated. In the multivariable models, household income below the municipal median (aRR:
6
7 248 3.24, 95% CI: 1.87-5.59) was the strongest risk factor for any IPV and EPDS was marginally
8
9 249 associated (aRR: 1.03, 95% CI: 1.00-1.07). There was no independent association between
10
11 250 maternal age (aRR: 0.99, 95% CI: 0.94-1.04), nulliparity (aRR: 1.18, 95% CI: 0.71-1.97), or
12
13 251 partner substance use increase (aRR: 0.73, 95% CI: 0.42-1.25) with IPV.
14
15
16
17 252
18
19 253
20
21
22 254

Discussion

23
24 255 In our study sample, almost a quarter (24.07%) of participants who gave birth during the
25
26 256 COVID-19 pandemic reported some form of perinatal IPV, including in the 12 months pre-
27
28 257 pregnancy, during pregnancy and post-partum. The most common forms of abuse included
29
30 258 emotional/psychological abuse and having partners who regularly exhibited controlling
31
32 259 behaviours. However, cases of sexual and physical abuse were also identified. Household
33
34 260 income was the strongest risk factor for perinatal IPV, and surprisingly, many hypothesized risk
35
36 261 factors (e.g., mental health, increased partner substance use etc.) were not significantly
37
38 262 associated with perinatal IPV in this sample.
39
40
41
42 263
43
44

45 264 By capturing a broad spectrum of forms of IPV, we are able to identify general controlling
46
47 265 behaviours that may have been normalized and not consider abusive, in addition to more distinct
48
49 266 forms of emotional/psychological, physical or sexual abuse. Many participants reported that their
50
51 267 partners insist on knowing where they are at all times, try to keep them from seeing their friends,
52
53 268 or would get angry if they spoke to someone they would be jealous of. Some of these behaviours
54
55
56
57
58
59
60

COVID-19 and perinatal IPV

1
2
3 269 may be magnified because of the safety concerns during COVID-19. The stay-at-home protocols
4
5 270 are important for infection control, however it raises ethical concerns if home is not a safe
6
7
8 271 place.⁴⁶ Someone may be isolated with a partner known to be abusive, or someone may begin to
9
10 272 exhibit abusive or controlling behaviours for the first time as a result of the increased stress and
11
12 273 anxiety associated with the COVID-19 pandemic.⁴⁷⁻⁴⁹
13
14
15 274

16
17 275 In this analysis, the factor most strongly associated with perinatal IPV was socio-economic
18
19 276 status, contributing to over three times the risk of IPV, while controlling for other risk factors.
20
21 277 The association between income and violence is well-established in the literature.⁵⁰ Consistent
22
23 278 with findings from national representative Canadian surveys,⁵¹ almost 30% of participants
24
25 279 reported household income loss because of COVID-19 protocols, and 25% reported that their
26
27 280 partners were essential workers, but of interest, both of these factors were not significantly
28
29 281 different by perinatal IPV status. This finding may be highlighting that the sustained stress of
30
31 282 lower socio-economic status poses a greater risk for perinatal IPV than the potential short-term
32
33 283 effects of COVID-19 related changes in financial stability. Socio-economic status is not
34
35 284 routinely collected as part of clinical practice, however it is consistently one of the most
36
37 285 powerful independent factors associated with IPV and may be a socio-demographic factor worth
38
39 286 collecting as part of routine clinical care.
40
41
42
43
44
45
46

47 288 In the wake of COVID-19, attention has been drawn to the responsibility of health care
48
49 289 practitioner's for screening for and addressing IPV, including investigating circumstances around
50
51 290 injuries.⁵² Within the obstetrical sphere, several commentaries have been written advocating for
52
53 291 integrating IPV assessments into ambulatory gynecologic care, post-partum recovery, mental
54
55
56
57
58
59
60

COVID-19 and perinatal IPV

1
2
3 292 health, and reproductive life planning.^{53–56} Systematic reviews and meta-analyses have identified
4
5 293 that strongest socio-demographic factors associated with elevated risk of perinatal IPV include
6
7
8 294 younger maternal age, single relationship status, visible minority status, lower socio-economic
9
10 295 status, and substance use.⁵⁰ Of interest within this study, several of the typical risk factors for
11
12 296 IPV were not significantly different by perinatal IPV status. This lends support for the
13
14
15 297 importance of universal IPV screening as risk factor-based screening may miss many cases in
16
17 298 need of help.
18

19 299
20
21 300 Despite the general pervasiveness of IPV and the increased risks posed by the COVID-19
22
23 301 pandemic, many health care providers are not well equipped to screen for violence or to take
24
25 302 action if IPV is identified.^{57,58} If children are in a home affected by violence there are legal
26
27 303 requirements to contact Children’s Aid as part of due diligence.⁵⁹ However, there are no such
28
29 304 requirements for IPV, reinforcing a systemic barrier to violence prevention and care. During the
30
31 305 pandemic period many services have introduced modifications to services, including closure of
32
33 306 physical offices, which has limited access to interventionable options. However, obstetrical
34
35 307 departments are one of the few services that have continued to see patients in person. Pregnancy
36
37 308 and the postpartum period presents a window of opportunity to identify and support people
38
39 309 experiencing violence who may have lost contact with other community services.
40
41
42
43
44

45 310

46
47 311 *Limitations*
48

49 312 Although a response rate of 42.58% is encouraging for an online survey administered to a patient
50
51 313 population, self-selection into this study was a potential source of selection bias. Although all
52
53 314 measures of IPV were self-reported and may underestimate the prevalence of IPV within this
54
55
56
57
58
59

COVID-19 and perinatal IPV

1
2
3 315 sample, the survey was designed to capture different forms of behaviours that may not be
4
5 316 perceived as abusive (e.g., insisting on know where you are at all times, keeping you from seeing
6
7 317 your friends) in addition to specific acts of emotional/psychological (e.g., insulting, scaring,
8
9 318 belittling etc.), physical (e.g. hitting, slapping, pushing), or sexual abuse (e.g., forced sexual
10
11 319 activity). We did not have a comparison group of participants prior to COVID-19 and were thus
12
13 320 unable to estimate the change in prevalence of IPV attributable to the increased stress of the
14
15 321 COVID-19 pandemic. Additionally, this study was unable to evaluate associations between IPV
16
17 322 and clinical outcomes as we did not have information on maternal or newborn outcomes.
18
19
20
21
22
23

324 Conclusion

24
25
26 325 Almost a quarter of this obstetrical study population reported some form of perinatal IPV,
27
28 326 including IPV experienced pre-pregnancy, during pregnancy and post-partum. Owing to
29
30 327 COVID-19 lock-down measures, many participants reported household income loss, changes to
31
32 328 childcare, and increased isolation during pregnancy and post-partum; however, it was the strong
33
34 329 social determinant of income that was most strongly associated with IPV. As the COVID-19
35
36 330 pandemic evolves, it is critical to prioritize the health and safety of the perinatal population in
37
38 331 public health planning to ensure that households are fully supported and risks are mitigated.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 335 **Declarations**

4 336 **Ethical approval**

5 337 This study was approved by the Ottawa Health Sciences Network Research Ethics Board
6 338 (Protocol number: 20170390-01H). All participants provided informed verbal consent. All
7 339 methods were performed in accordance with standard ethical guidelines and regulations
8 340 (Declaration of Helsinki)

9 341

10 342 **Consent for publication**

11 343 Not applicable

12 344

13 345 **Availability of data and materials**

14 346 The datasets generated and analyzed during the current study are not publicly available due to
15 347 The Ottawa Hospital privacy protocols, but with a data sharing agreement, de-identified data, the
16 348 data dictionary, and ethics protocol are available from the corresponding author

17 349

18 350 **Competing interests**

19 351 All authors declare no conflicts of interest

20 352

21 353 **Funding**

22 354 The Ottawa Hospital Academic Medical Organization (TOHAMO): TOH-20-005

23 355

24 356 **Author Contributions:**

25 357 KM, KD, RT, CB, OF, AH, RRW, KS, DE conceived and designed the study. KS, MW, DE
26 358 provided clinical expertise and content. RT conducted the statistical analyses and KM, DF, YG,
27 359 MM, DC, SW provided methodological and analytic expertise. CB, OF, KD collected the data.
28 360 MOG is the patient partner. All authors critically reviewed the manuscript and approved the final
29 361 version. KM and DE have primary responsibility for the final content.

30 362

31 363 **Acknowledgements**

32 364 We would like to acknowledge all the participants who took the time to respond to this survey.
33 365 We thank Drs Jasmine Gandhi and Mark Kaluzienski for support developing the perinatal mental
34 366 health response study protocols.

35 367

36 368

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

*COVID-19 and perinatal IPV***Figure 1. Different forms of controlling behaviour from partner during COVID-19 (n=216)**

370

*Note: Measured using items from the World Health Organization Multi-Country Study on

Domestic Violence

373

374

375

Figure 2. Forms and timing of perinatal IPV (n=216)

377

*Note Participants can report multiple forms of IPV. Cases of physical and sexual abuse were

identified, but suppressed because of small cell sizes

380

For peer review only

COVID-19 and perinatal IPV

References

1. Chandan JS, Taylor J, Bradbury-Jones C, Nirantharakumar K, Kane E, Bandyopadhyay S. COVID-19: A public health approach to manage domestic violence is needed. *Lancet Public Heal.* 2020;2667(20):30112. doi:10.1016/S2468-2667(20)30112-2
2. de Girolamo G, Cerveri G, Clerici M, et al. Mental Health in the Coronavirus Disease 2019 Emergency-The Italian Response. *JAMA Psychiatry.* 2020:2019-2021. doi:10.1001/jamapsychiatry.2020.1276
3. Mazza M, Marano G, Lai C, Janiri L, Sani G. Danger in Danger: Interpersonal Violence During COVID-19 Quarantine. *Psychiatry Res.* 2020;289. doi:10.1016/j.psychres.2020.113046
4. Roesch E. Violence against women during Covid-19 pandemic restrictions. *Br Med J.* 2020. doi:10.1136/bmj.m1712
5. Galea S, Merchant RM, Lurie N. The Mental Health Consequences of COVID-19 and Physical Distancing: The Need for Prevention and Early Intervention. *JAMA Intern Med.* 2020;[Published. doi:10.1001/jamainternmed.2020.1562
6. Breiding MJ, Basile KC, Smith SG, Black MC, Mahendra R. Intimate Partner Violence Surveillance: Uniform Definitions and Recommended Data Elements. *Natl Cent Inj Prev Control Centers Dis Control Prev.* 2015;36:706-707. doi:10.1136/bmj.328.7440.595
7. UN Women. *Policy Brief: The Impact of Covid-19 on Women.*; 2020. <https://www.unwomen.org/-/media/headquarters/attachments/sections/library/publications/2020/policy-brief-the-impact-of-covid-19-on-women-en.pdf?la=en&vs=5029>.
8. Usher K, Bhullar N, Durkin J, Gyamfi N, Jackson D. Family Violence and COVID-19: increased vulnerability and reduced options for support. *Int J Ment Health Nurs.* 2020. doi:10.1111/inm.12735
9. Van Gelder N, Peterman A, Potts A, et al. COVID-19: Reducing the risk of infection might increase the risk of intimate partner violence. *EClinicalMedicine.* 2020;21:100348. doi:10.1016/j.eclinm.2020.100348
10. Violence Against Women Learning Network. *COVID-19 & Gender-Based Violence in Canada : Key Issues and Recommendations.* London, Ontario; 2020.
11. World Health Organization. *Global Status Report on Violence Prevention.*; 2014. doi:10.1007/s13398-014-0173-7.2
12. Hahn C, Gilmore A, Aguayo R, Rheingold A. Perinatal Intimate Partner Violence. *Obstet Gynecol Clin North Am.* 2018;45(3):535-547. doi:10.1016/j.physbeh.2017.03.040
13. Solomon MD, McNulty EJ, Rana JS, et al. The COVID-19 Pandemic and the incidence of Acute Myocardial Infarction. *N Engl J Med.* 2020;e-pub ahea:10-12.
14. Frankfurter C, Buchan TA, Kobulnik J, et al. Reduced Rate of Hospital Presentations for Heart Failure During the COVID-19 Pandemic in Toronto, Canada. *Can J Cardiol.* 2020:1-5. doi:10.1016/j.cjca.2020.07.006
15. Olding J, Zisman S, Olding C, Fan K. Penetrating trauma during a global pandemic: Changing patterns in interpersonal violence, self-harm and domestic violence in the Covid-19 outbreak. *Surgeon.* 2020;(xxxx). doi:10.1016/j.surge.2020.07.004
16. Morris D, Rogers M, Kissmer N, Du A, Dufourq N. Impact of lockdown measures implemented during the COVID-19 pandemic on the burden of trauma presentation to a regional emergency department in Kwa-Zulu Natal, South Africa. *African J Emerg Med.*

COVID-19 and perinatal IPV

- 2020;in press(January).
- 427 17. Garstang J, Debelles G, Anand I, et al. Effect of COVID-19 lockdown on child protection
428 medical assessments: A retrospective observational study in Birmingham, UK. *BMJ Open*.
429 2020;10(9):1-6. doi:10.1136/bmjopen-2020-042867
 - 430 18. Barbara G, Facchin F, Micci L, et al. COVID-19, Lockdown, and Intimate Partner
431 Violence: Some Data from an Italian Service and Suggestions for Future Approaches. *J*
432 *Women's Heal*. 2020;29(10):1239-1242. doi:10.1089/jwh.2020.8590
 - 433 19. Piquero AR, Riddell JR, Bishopp SA, Narvey C, Reid JA, Piquero NL. Staying Home,
434 Staying Safe? A Short-Term Analysis of COVID-19 on Dallas Domestic Violence. *Am J*
435 *Crim Justice*. 2020. doi:10.1007/s12103-020-09531-7
 - 436 20. Leslie E, Wilson R. Sheltering in place and domestic violence: Evidence from calls for
437 service during COVID-19. *J Public Econ*. 2020;189:104241.
438 doi:10.1016/j.jpubeco.2020.104241
 - 439 21. Sutherland M, McKenney M, Elkbulli A. Gun violence during COVID-19 pandemic:
440 Paradoxical trends in New York City, Chicago, Los Angeles and Baltimore. *Am J Emerg*
441 *Med*. 2020;(xxxx):5-6. doi:10.1016/j.ajem.2020.05.006
 - 442 22. Statistics Canada. *Police-Reported Crime Incidents down during the Early Months of the*
443 *Pandemic , While Domestic Disturbance Calls Increase*. Ottawa; 2020.
444 [https://www150.statcan.gc.ca/n1/en/daily-quotidien/200901/dq200901a-](https://www150.statcan.gc.ca/n1/en/daily-quotidien/200901/dq200901a-eng.pdf?st=jbSqjflM)
445 [eng.pdf?st=jbSqjflM](https://www150.statcan.gc.ca/n1/en/daily-quotidien/200901/dq200901a-eng.pdf?st=jbSqjflM).
 - 446 23. Payne JL, Morgan A, Piquero AR. COVID-19 and social distancing measures in
447 Queensland, Australia, are associated with short-term decreases in recorded violent crime.
448 *J Exp Criminol*. 2020. doi:10.1007/s11292-020-09441-y
 - 449 24. Hodgkinson T, Andresen MA. Show me a man or a woman alone and I ' ll show you a
450 saint : Changes in the frequency of criminal incidents during the COVID-19 pandemic. *J*
451 *Crim Justice*. 2020;(January).
 - 452 25. Mohler G, Bertozzi AL, Carter J, et al. Impact of social distancing during COVID-19
453 pandemic on crime in Los Angeles and Indianapolis. *J Crim Justice*. 2020;68(March).
454 doi:10.1016/j.jcrimjus.2020.101692
 - 455 26. Lindberg L, VandeVusse D, Mueller A, Kirstein J, Mariell. *Early Impacts of the COVID-*
456 *19 Pandemic: Findings from the 2020 Guttmacher Survey of Reproductive Health*
457 *Experiences*. New York; 2020. www.guttmacher.org.
 - 458 27. Jetelina KK, Knell G, Molsberry RJ. Changes in intimate partner violence during the early
459 stages of the COVID-19 pandemic in the USA. *Inj Prev*. 2020;(1):1-5.
460 doi:10.1136/injuryprev-2020-043831
 - 461 28. Id SE, Jenkins M, Gendall P, et al. Psychological distress, anxiety, family violence,
462 suicidality, and wellbeing in New Zealand during the COVID-19 lockdown : A cross-
463 sectional study. *PLoS One*. 2020;15(11):1-19. doi:10.1371/journal.pone.0241658
 - 464 29. Abou Ghayda R, Li H, Hwa Lee K, et al. COVID-19 and Adverse Pregnancy Outcome: A
465 Systematic Review of 104 Cases. *J Clin Med*. 2020;(1-15):3441. doi:10.3390/jcm9113441
 - 466 30. Di Mascio D, Khalil A, Saccone G, et al. Outcomes of coronavirus spectrum infections
467 (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis.
468 *Am J Obstet Gynecol*. 2020;(January).
 - 469 31. Novoa RH, Quintana W, Llancarí P, Urbina-quispe K, Guevara-ríos E, Ventura W.
470 Maternal clinical characteristics and perinatal outcomes among pregnant women with
471 coronavirus disease 2019 . A systematic review. *Travel Med Infect Dis*. 2021;39(June
472

COVID-19 and perinatal IPV

- 2020):101919. doi:10.1016/j.tmaid.2020.101919
32. Vardhelli V, Pandita A, Pillai A, Badatya SK. Perinatal COVID-19: review of current evidence and practical approach towards prevention and management. *Eur J Pediatr*. 2020. doi:10.1007/s00431-020-03866-3
33. Zaigham M, Andersson O. Maternal and perinatal outcomes with COVID-19: A systematic review of 108 pregnancies. *Acta Obstet Gynecol Scand*. 2020;99(7):823-829. doi:10.1111/aogs.13867
34. Yee J, Kim W, Han JM, et al. Clinical manifestations and perinatal outcomes of pregnant women with COVID-19: a systematic review and meta-analysis. *Sci Rep*. 2020;10(1):1-7. doi:10.1038/s41598-020-75096-4
35. Di Toro F, Gjoka M, Di Lorenzo G, et al. Impact of COVID-19 on maternal and neonatal outcomes: a systematic review and meta-analysis. *Clin Microbiol Infect*. 2020;(xxxx). doi:10.1016/j.cmi.2020.10.007
36. Zambrano LD, Ellington S, Strid P, et al. Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status — United States, January 22–October 3, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(44):1641-1647. doi:10.15585/mmwr.mm6944e3
37. Hessami K, Romanelli C, Chiurazzi M, Cozzolino M. COVID-19 pandemic and maternal mental health: a systematic review and meta-analysis. *J Matern Neonatal Med*. 2020. doi:10.1080/14767058.2020.1843155
38. Preis H, Mahaffey B, Heiselman C, Lobel M. Pandemic-related pregnancy stress and anxiety among women pregnant during the coronavirus disease 2019 pandemic. *Am J Obstet Gynecol MFM*. 2020;2(3):100155. doi:10.1016/j.ajogmf.2020.100155
39. Government of Canada. Coronavirus disease 2019 (COVID-19): Epidemiology update.
40. The Ottawa Hospital. High-risk twin pregnancy during COVID-19 pandemic. https://ohfoundation.ca/be-inspired/high-risk-twin-pregnancy-during-covid-19-pandemic/?utm_source=vitallinks-en&utm_medium=email&utm_campaign=meagan-gordon&utm_content=08-06-20-vl-meagan. Published 2020. Accessed September 2, 2020.
41. Garcia-Moreno C, Jansen HAFM, Ellsberg M, Heise L, Watts C. WHO Multi-Country Study on Women's Health and Domestic Violence Against Women: Report on the First Results. *World Heal Organ*. 2005:55-89.
42. Ottawa Public Health. Socio-demographic data and population projects. General Population Health. <https://www.ottawapublichealth.ca/en/reports-research-and-statistics/sociodemographics.aspx#Origin-and-Identity->. Published 2020. Accessed December 17, 2020.
43. Statistics Canada. Distribution of total income by census family type and age of older partner, parent or individual. doi:<https://doi.org/10.25318/1110001201-eng>
44. SAS Institute Inc. SAS Institute Inc. 2017.
45. Azur MJ, Stuart EA, Frangakis C, Leaf PJ. Multiple imputation by chained equation: What is it and how does it work. *Int J Methods Psychiatr Res*. 2011;20(1):40-49. doi:10.1002/mpr
46. Bruno B, Shalowitz DI, Arora KS. Ethical challenges for women's healthcare highlighted by the COVID-19 pandemic. *J Med Ethics*. 2020:medethics-2020-106646. doi:10.1136/medethics-2020-106646
47. Usher K, Bhullar N, Durkin J, Gyamfi N, Jackson D. Family violence and COVID-19:

COVID-19 and perinatal IPV

- 1
2
3 519 Increased vulnerability and reduced options for support. *Int J Ment Health Nurs*. 2020.
4 520 doi:10.1111/inm.12735
- 5 521 48. John N, Casey S, Carino G, McGovern T. Lessons never learned: Crisis and gender-based
6 522 violence. *Dev World Bioeth*. 2020;00:1-4. doi:10.1111/dewb.12261
- 7 523 49. Roesch E, Amin A, Gupta J, García-Moreno C. Violence against women during covid-19
8 524 pandemic restrictions. *BMJ*. 2020;369(May):2-3. doi:10.1136/bmj.m1712
- 9 525 50. Pastor-Moreno G, Ruiz-Pérez I, Henares-Montiel J, Petrova D. Intimate partner violence
10 526 during pregnancy and risk of fetal and neonatal death: a meta-analysis with socioeconomic
11 527 context indicators. *Am J Obstet Gynecol*. 2019;(February). doi:10.1016/j.ajog.2019.07.045
- 12 528 51. Statistics Canada. *Canadian Perspectives Survey Series 1 : Impacts of COVID-19*. Ottawa;
13 529 2020. [https://www150.statcan.gc.ca/n1/en/daily-quotidien/200408/dq200408c-](https://www150.statcan.gc.ca/n1/en/daily-quotidien/200408/dq200408c-eng.pdf?st=AhCEAktc)
14 530 [eng.pdf?st=AhCEAktc](https://www150.statcan.gc.ca/n1/en/daily-quotidien/200408/dq200408c-eng.pdf?st=AhCEAktc).
- 15 531 52. Bradley N., DiPasquale AM, Dillabough K, Schneider PS. Health care practitioners'
16 532 responsibility to address intimate partner violence related to the COVID-19 pandemic.
17 533 *Can Med Assoc J*. 2020:1-2. doi:10.1503/cmaj.200634
- 18 534 53. Cohen MA, Powell AM, Coleman JS, Keller JM, Livingston A, Anderson JR. Special
19 535 ambulatory gynecologic considerations in the era of coronavirus disease 2019 (COVID-
20 536 19) and implications for future practice. *Am J Obstet Gynecol*. 2020;223(3):372-378.
21 537 doi:10.1016/j.ajog.2020.06.006
- 22 538 54. Sadler M, Leiva G, Olza I. COVID-19 as a risk factor for obstetric violence. *Sex Reprod*
23 539 *Heal Matters*. 2020;28(1). doi:10.1080/26410397.2020.1785379
- 24 540 55. Choi K, Records K, Low LK, et al. Promotion of Maternal–Infant Mental Health and
25 541 Trauma-Informed Care During the Coronavirus Disease 2019 Pandemic. *J Obstet Gynecol*
26 542 *Neonatal Nurs*. 2020;(August):1-7. doi:10.1016/j.jogn.2020.07.004
- 27 543 56. Tang K, Gaoshan J, Ahonsi B. Sexual and reproductive health (SRH): a key issue in the
28 544 emergency response to the coronavirus disease (COVID- 19) outbreak. *Reprod Health*.
29 545 2020;17(59). doi:10.1186/s12978-020-0900-9
- 30 546 57. Rabin RF, Jennings JM, Campbell JC, Bair-Merritt MH. Intimate Partner Violence
31 547 Screening Tools. A Systematic Review. *Am J Prev Med*. 2009;36(5):439-445.e4.
32 548 doi:10.1016/j.amepre.2009.01.024
- 33 549 58. Doherty OL, Hegarty K, Ramsay J, Davidson L, Feder G, Taft A. Screening women for
34 550 intimate partner violence in healthcare settings (Review). *Cochrane Database Syst Rev*
35 551 *Screenin*. 2015;(7). doi:10.1002/14651858.CD007007.pub3. www.cochranelibrary.com
- 36 552 59. Government of Ontario. *Child, Youth and Family Services Act , 2017, Chapter 14*.
37 553 Canada; 2017:1-166. <https://www.ontario.ca/laws/statute/17c14>.
38 554
39 555
40 556

COVID-19 and perinatal IPV

557 Table 1. General characteristics of study participants who have given birth since the COVID-19 pandemic
 558 began (n=216)
 559

Variables	IPV		Total N=216	p- values
	Yes (n=52)	No (164)		
Demographic characteristics				
Maternal Age in years (median, IQR)	32 (30-34)	33 (30-36)	33 (30-36)	0.089
Infant age in days at time of interview (med, IQR)	80 (67-89)	75 (65-90)	76 (66-90)	0.375
Month of Delivery in 2020				
March	11 (21.15)	28 (17.07)	39 (18.06)	0.800
April	21 (40.38)	61 (37.20)	82 (37.96)	
May	13 (25.00)	51 (31.10)	64 (29.63)	
June	7 (13.46)	24 (14.63)	31 (14.35)	
Nulliparous vs multiparous	32 (61.54)	86 (52.44)	118 (54.63)	0.251
Race or Ethnicity¹				
White	31 (59.62)	116 (70.73)	147 (68.06)	0.134
Asian – South/East/South-East	9 (17.31)	22 (13.41)	31 (14.35)	0.485
Middle Eastern	8 (15.38)	10 (6.10)	18 (8.33)	0.035
Black	5 (9.62)	12 (7.32)	17 (7.87)	0.592
Another PoC group	9 (17.31)	16 (9.76)	25 (11.57)	0.138
Born in Canada vs immigrated	34 (65.38)	125 (76.22)	159 (73.61)	0.122
Marital status: Married/common law vs single/another status	48 (92.31)	156 (95.12)	204 (94.44)	0.440
Completed college diploma or under-graduate degree	44 (84.62)	144 (87.80)	188 (87.04)	0.551
Language(s) comfortable speaking¹				
Speaks English	51 (98.08)	161 (98.17)	212 (98.15)	0.965
Speaks French	19 (36.54)	55 (33.54)	74 (34.26)	0.691
Speaks another language	9 (17.31)	20 (12.20)	29 (13.43)	0.346
Income				
Dwelling owned vs rented	29 (55.77)	122 (74.39)	151 (69.91)	0.011
Combined household income below Ottawa median ²	34 (65.38)	46 (28.05)	80 (37.04)	<0.001
COVID-19 related household stress				
Any household income loss	19 (36.54)	45 (27.44)	64 (29.63)	0.211
Partner is essential worker	12 (23.08)	43 (26.22)	55 (25.46)	0.650
Partner substance use increased	12 (23.08)	33 (20.12)	45 (20.83)	0.648
Children's schedule				
Children stopped going to school or daycare	17 (32.69)	67 (40.85)	84 (38.89)	0.515
Children's schedule did not change	-	-	14 (6.48)	
No children	32 (61.54)	86 (52.44)	118 (54.63)	
Isolation due to COVID-19 restrictions				
No baby shower or planned celebration	29 (55.77)	70 (42.68)	99 (45.83)	0.099
Family member couldn't come to stay with me as planned	30 (57.69)	78 (47.56)	108 (50.00)	0.203
Friends and family could not visit my new baby	41 (78.85)	129 (78.66)	170 (78.70)	0.977

COVID-19 and perinatal IPV

Missed out on community resources	46 (88.46)	137 (83.54)	183 (84.72)	0.390
Mental health				
Pre-existing anxiety	13 (25.00)	30 (18.29)	43 (19.91)	0.291
Pre-existing depression	7 (13.46)	22 (13.41)	29 (13.43)	0.993
Post-partum depression (EPDS 13 cut-off)	20 (38.46)	44 (26.83)	64 (29.63)	0.109
EPDS Score (med, IQR)	10 (5-14)	8 (4-13)	8 (4-13)	0.130
Healthcare experiences				
Alone for all labour and delivery	-	-	16 (7.41)	0.928
Wear a mask during delivery	22 (42.31)	75 (45.73)	97 (44.91)	0.665
Any post-partum emergency department visit for mother or infant	11 (21.15)	31 (18.90)	42 (19.44)	0.721
Coping mechanisms				
Positive coping mechanisms ³	49 (94.23)	160 (97.56)	209 (96.76)	0.237
Negative coping mechanisms ⁴	38 (73.08)	101 (61.59)	139 (64.35)	0.132

- Cell sizes ≤ 5 and are suppressed

1. Participants can pick multiple race/ethnic groups or languages

2. Missing data=24 cases

3. Positive coping mechanisms include: yoga, exercising, donating to charity, connecting with friends/family

4. Negative coping mechanism include: sleeping more or less; over/under eating, acting aggressively

COVID-19 and perinatal IPV

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

568 Table 2. Bivariable and Multivariable log binomial regression models to assess factors associated with perinatal IPV (n=216)

569

Co-Variables	RR (95% CI)	p-value	ARR (95% CI)	p-value
Maternal Age in years (median, IQR)	0.95 (0.90-1.00)	0.082	0.99 (0.94-1.04)	0.660
Nulliparous vs multiparous	1.33 (0.76-2.32)	0.319	1.18 (0.71-1.97)	0.529
Household income below vs above Ottawa median ¹	3.66 (2.07-6.48)	<0.001	3.24 (1.87-5.59)	<0.001
EPDS Score (continuous)	1.04 (1.00-1.10)	0.040	1.03 (1.00-1.07)	0.077
Partner substance use increased	1.14 (0.60-2.17)	0.691	0.73 (0.42-1.25)	0.249

570


1. Missing data for household income was imputed by multiple imputation using chained equations and models were averaged across 10 imputed datasets

571

572

573


1
2 **Figure 1. Different forms of controlling behaviour from partner during COVID-19 (n=216)**
3



28
29 *Note: Measured using items from the World Health Organization Multi-Country Study on Domestic Violence
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Figure 2. Forms and timing of perinatal IPV (n=216)



*Note: Participants can report multiple forms of IPV. Cases of physical and sexual abuse were identified, but suppressed because of small cell sizes

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract Included: abstract The study is a cross-sectional study
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found Included: Abstract, methods and results section
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported Included: Introduction Section (p.4-6)
Objectives	3	State specific objectives, including any prespecified hypotheses Included: Introduction Section (p. 6)
Methods		
Study design	4	Present key elements of study design early in the paper Included: Methods –Study design and recruitment (p. 7-8)
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Included: Methods – Study setting and context, Study design and recruitment (p. 7-8)
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up na (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed na
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Included: Methods – Outcomes, Covariables (p.8-10)
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Included: Methods – Outcomes, Covariables (p.8-10)
Bias	9	Describe any efforts to address potential sources of bias Included: Methods Section – Study design and recruitment (p. 7-8), Analysis (p.11)
Study size	10	Explain how the study size was arrived at A sample size was not calculated because all eligible patients were contacted
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Included: Methods – Outcomes, Covariables (p.8-10), Analysis (p.11)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Statistical methods

12 (a) Describe all statistical methods, including those used to control for confounding

Included: Methods Section – Analysis (p.11)

(b) Describe any methods used to examine subgroups and interactions

Included: Methods Section – Analysis (p.11)

(c) Explain how missing data were addressed

Methods Section – Analysis (p.11)(d) *Cohort study*—If applicable, explain how loss to follow-up was addressedIncluded: na

(e) Describe any sensitivity analyses

NA

Continued on next page

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

Participants	13*	<p>(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed Included: The description of the study population is described in the Results Section. (p.12)</p> <p>(b) Give reasons for non-participation at each stage Included: Participation and response rate are described in the Results Section. (p.12)</p> <p>(c) Consider use of a flow diagram (Figure 1)</p>
Descriptive data	14*	<p>(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Included: Results Section – (p 12-13)</p> <p>(b) Indicate number of participants with missing data for each variable of interest Missing data is foot-noted in each table</p> <p>(c) <i>Cohort study</i>—Summarise follow-up time (eg, average and total amount) Included: na</p>
Outcome data	15*	<p><i>Cohort study</i>—Report numbers of outcome events or summary measures over time Included: na</p>
Main results	16	<p>(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included Included: Results Section – (p 13-14), Table 2</p> <p>(b) Report category boundaries when continuous variables were categorized Included: Results Section – (p 12), Table 1</p> <p>(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period</p>
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18	Summarise key results with reference to study objectives Included: Discussion Section (p.14-17)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias Included: Discussion Section (p.16)
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence Included: Discussion Section (p.14-17)
Generalisability	21	Discuss the generalisability (external validity) of the study results Included: Discussion Section (p. 16)
Other information		
Funding	22	<p>Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based Funding: The Ottawa Hospital Academic Medical Organization (TOHAMO): TOH-20-005</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

For peer review only

BMJ Open

COVID-19 and Perinatal Intimate Partner Violence: A cross-sectional survey of pregnant and post-partum individuals in the early stages of the COVID-19 pandemic

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-049295.R1
Article Type:	Original research
Date Submitted by the Author:	13-Mar-2021
Complete List of Authors:	Muldoon, Katherine; Ottawa Hospital Research Institute; University of Ottawa, Obstetrics and Gynecology Denize, Kathryn; Ottawa Hospital Research Institute Talarico, Robert; Ottawa Hospital Research Institute Boisvert, Carlie; Ottawa Hospital Research Institute; University of Ottawa, Faculty of Medicine Frank, Olivia; Ottawa Hospital Research Institute; Columbia University, Mailman School of Public Health Harvey, Alysha; Ottawa Hospital Research Institute White, Ruth; Ottawa Hospital Research Institute Fell, DB; University of Ottawa, School of Epidemiology and Public Health; Children's Hospital of Eastern Ontario Research Institute O'Hare-Gordon, Meagan Ann; Ottawa Hospital Research Institute Guo, Yanfang; Children's Hospital of Eastern Ontario, BORN Ontario; University of Ottawa, School of Epidemiology and Public Health Murphy, Malia; Ottawa Hospital Research Institute, Clinical Epidemiology Program Corsi, Daniel J.; Ottawa Hospital Research Institute; Children's Hospital of Eastern Ontario Research Institute Sampsel, Kari; University of Ottawa, Emergency Medicine; Ottawa Hospital Research Institute Wen, Shi Wu; Ottawa Hospital Research Institute; University of Ottawa, School of Epidemiology and Public Health Walker, Mark; Ottawa Hospital Research Institute, Clinical Epidemiology Program; University of Ottawa, Obstetrics and Gynecology El-Chaar, Darine; Ottawa Hospital Research Institute, Clinical Epidemiology Program; University of Ottawa, Faculty of Medicine
Primary Subject Heading:	Obstetrics and gynaecology
Secondary Subject Heading:	Epidemiology, Public health
Keywords:	COVID-19, OBSTETRICS, Maternal medicine < OBSTETRICS, PUBLIC HEALTH, SOCIAL MEDICINE

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

*COVID-19 and perinatal IPV***COVID-19 and Perinatal Intimate Partner Violence: A cross-sectional survey of pregnant and post-partum individuals in the early stages of the COVID-19 pandemic**

Katherine A. Muldoon, PhD¹, Kathryn M. Denize, MSc¹., Robert Talarico, MSc¹., Carlie Boisvert,² Olivia Frank,¹ Alysha LJ Harvey, MSc¹., Ruth Rennicks White, RN¹., Deshayne B. Fell^{3,4}, PhD., Meagan Ann O'Hare Gordon,¹ Yanfang Guo,^{1,3,4} Malia SQ Murphy,¹ Daniel Corsi,^{1,3,4} Kari Sampsel MD,^{1,2} Shi Wu Wen, PhD,^{1,3} Mark Walker, MD,^{1,2,3} Darine El-Chaâr, MD^{1,2}

1. Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
2. Faculty of Medicine, The Ottawa Hospital and University of Ottawa, Ottawa, Ontario, Canada
3. School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario
4. Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario

Send correspondence to: Dr. Katherine Muldoon
Assistant Professor, Department of Obstetrics and Gynecology,
University of Ottawa
Senior Research Associate, Ottawa Hospital Research Institute
501 Smyth Road
Ottawa, Ontario
K1H-8L6
Email: kmuldoon@ohri.ca
Telephone: 613-737-8899 x 77235

Manuscript word count: 3449 (3500 max)

Abstract word count: 344 (350 max)

Key words: intimate partner violence, perinatal IPV, COVID-19, violence, abuse, perinatal health

*COVID-19 and perinatal IPV***Abstract**

Objective: The objectives of this study were to: 1) document violent and controlling behaviours within intimate partnerships during the perinatal period; and 2) determine individual, interpersonal and household-level factors influencing the risk of perinatal intimate partner violence (IPV).

Design: Cross-sectional survey

Setting: The Ottawa Hospital, Department of Obstetrics and Gynecology, Ottawa, Ontario

Participants: Patients who gave birth at The Ottawa Hospital and were >20 days post-partum between March 17th-June 16th 2020.

Main outcomes and measures: Perinatal IPV was defined as regular controlling behaviours or act-based forms of emotional/physical/sexual abuse in the 12 months before pregnancy, during pregnancy and/or post-partum. Log-binomial multivariable regression models were used to compute adjusted risk ratios (aRR) and 95% confidence intervals (CI) to identify potential risk factors for IPV: maternal age, post-partum depression, parity, increase in partner substance use, and household income.

Results: Among 216 participants, the median maternal age was 33 years (interquartile range (IQR): 30-36). In total, 52 (24.07%) reported some form of perinatal IPV, 37 (17.13%) reported regular controlling behaviour, and 9 (4.17%) reported both. Household income below the municipal median was the strongest risk factor for perinatal IPV (aRR: 3.24, 95% CI: 1.87-5.59). There was no apparent association between maternal age (aRR: 0.99, 95% CI: 0.94-1.04), post-partum depression (aRR: 1.03, 95% CI: 1.00-1.07), nulliparity (aRR: 1.18, 95% CI: 0.71-1.97), or increases in partner substance use (aRR: 0.73, 95% CI: 0.42-1.25) with IPV.

Conclusion: 1 in 4 individuals in this study experienced perinatal IPV. Household income was the strongest risk factor, and surprisingly, many hypothesized risk factors (e.g., mental health, partner substance use etc.) were not significantly associated with perinatal IPV in this sample. This highlights the challenges in both measuring IPV and identifying individuals exposed to perinatal IPV during the high stress of the COVID-19 pandemic.

Abstract word count: 298 (300 max)

Key words: intimate partner violence, perinatal IPV, COVID-19-19, violence, abuse, perinatal health

*COVID-19 and perinatal IPV***Strengths and Limitations**

- This study uses a detailed definition of perinatal IPV including regular controlling behaviours, emotional, physical and sexual abuse during three perinatal time periods: pre-pregnancy, prenatal and post-partum periods
- There is detailed information on household stressors and changes directly attributable to the COVID-19 pandemic protocols
- There is detailed information on ethnicity, socio-economic status, and partner characteristics
- Self-selection and non-response bias is a source of selection bias and under-reporting of IPV and residual confounding is a source of measurement bias
- This study does not have a comparison group of participants prior to COVID-19 and is unable to estimate changes in perinatal IPV directly attributable to the stress of the COVID-19 pandemic.

Funding

This work was supported by The Ottawa Hospital Academic Medical Organization (TOHAMO): TOH-20-005.

Competing interests

All authors declare no conflicts of interest

COVID-19 and perinatal IPV

20

21 Introduction

22 The evolving COVID-19 pandemic continues to cause extreme stress, unease and fear, all factors
23 that can increase the risk of intimate partner violence (IPV).¹⁻⁵ IPV broadly encompasses any
24 form of emotional abuse, threatening behaviour, psychological harm, physical violence or sexual
25 violence from a current or former intimate partner or spouse.⁶ Shortly after the initial declaration
26 of COVID-19 as a global pandemic on March 11th 2020, the United Nations released a statement
27 on March 27th 2020 warning of increased risks of IPV,⁷ in addition to the health-related
28 consequences of COVID-19 infection.⁸⁻¹⁰ It is estimated that over 30% of women have
29 experienced IPV in their lives¹¹ and 3-9% of individuals experience perinatal IPV, defined as
30 violence or abuse that occurs 12 months prior to pregnancy, during pregnancy and up to one year
31 post-partum.¹² To date, there is limited data on the prevalence and risk factors of perinatal IPV
32 during the COVID-19 pandemic, despite the rising global concern for both pregnant people and
33 the increase in violence.

34

35 The primary sources of data on violence during the COVID-19 pandemic have come from
36 emergency departments (ED), policing or crime data, and online surveys. Most EDs saw drastic
37 decreases in all-cause admissions immediately following the COVID-19 lockdown.¹³⁻¹⁵
38 Investigations of cause-specific ED admissions varied, where some studies identified increases in
39 IPV or assault-based cases^{16,17} while others reported decreases.^{18,19} Mixed patterns have also
40 been observed in crime data from police departments, where some settings reported increases in
41 domestic violence cases,²⁰⁻²² some found decreases,^{23,24} and others identified no detectable
42 changes.^{25,26} An online survey of over 2000 cis-gendered women from the United States found

COVID-19 and perinatal IPV

1
2
3 43 that 16% had experienced IPV since the beginning of 2020, including 11% being emotionally
4
5 44 abused, 5% forced to engage in unwanted sexual activity, and 6% physically harmed.²⁷ Another
6
7
8 45 survey of over 2400 Americans found that 18% had a history of IPV, and of those, 17% reported
9
10 46 that IPV had gotten worse since COVID-19 began.²⁸ A representative sample of over 2000 adults
11
12 47 in New Zealand found 10% experienced some form of sexual, physical or emotional abuse
13
14 48 during the first month of the COVID-19 pandemic.²⁹ Collectively, these studies highlight the
15
16 49 complexities of assessing and evaluating patterns of violence and IPV during the pandemic,
17
18 50 however none have included information on pregnancy or post-partum status, limiting our
19
20
21 51 understanding of perinatal IPV during COVID-19.
22
23
24 52

25
26 53 Adverse maternal and infant outcomes associated with COVID-19 infection, include higher risk
27
28 54 of pre-term birth, cesarean birth, and some cases of fetal and maternal death.^{30–36} A recent US
29
30 55 Centers for Disease Control surveillance report of 24,434 pregnant individuals with COVID-19
31
32 56 infection identified higher risk of admission to intensive care, invasive ventilation, and death
33
34 57 compared to non-pregnant individuals of reproductive age.³⁷ A systematic review of maternal
35
36 58 mental health during COVID-19 found significant increases in risk of anxiety and higher scores
37
38 59 on the Edinburgh Postnatal Depression Survey (EPDS) among pregnant and post-partum
39
40
41 60 individuals during COVID-19 compared to pre-COVID-19.³⁸ A new scale, called the Pandemic
42
43 61 Related Pregnancy Stress (PREPS) scale was developed and found that a history of abuse was an
44
45 62 independent predictor of moderate or severe anxiety during COVID-19.³⁹ To our knowledge, this
46
47 63 is the only study that captured information on historical abuse among a perinatal sample,
48
49
50 64 however there was no information on perinatal IPV.
51
52
53
54
55
56
57
58
59
60

COVID-19 and perinatal IPV

1
2
3 65 Given the limited evidence base on perinatal IPV during COVID-19 and growing concern about
4
5 66 maternal health and safety, the goal of this study was to investigate perinatal IPV among those
6
7 67 who gave birth during the COVID-19 pandemic. The objectives of this study were to: 1)
8
9 68 document violent and controlling behaviours within intimate partnerships during the perinatal
10
11 69 period; and 2) determine individual, interpersonal and household-level factors influencing the
12
13 70 risk of perinatal intimate partner violence (IPV).
14
15
16
17
18

72 Methods*73 Study setting and context*

21
22
23 74 This study took place in Ottawa, Ontario, the fourth largest city in Canada with a census
24
25 75 metropolitan population of 1.3 million. The provincial government declared a state of emergency
26
27 76 on March 17, 2020. As a result, most public establishments were closed (e.g., schools, childcare
28
29 77 centers, libraries, recreational centers, restaurants, etc.) and most workplaces transitioned to
30
31 78 remote work, where possible. At the time of the study (June, 2020), the cumulative number of
32
33 79 confirmed COVID-19 cases in Ottawa was 2 650 (40 161 cases in the province of Ontario, and
34
35 80 119 451 cases in Canada.⁴⁰
36
37
38
39
40
41

42 82 This study was conducted at The Ottawa Hospital, a multi-site tertiary-care facility with two
43
44 83 obstetrical wards across the city. The Department of Obstetrics, Gynaecology and Newborn Care
45
46 84 implemented safety protocols whereby all pregnant patients underwent symptomatic screening
47
48 85 for COVID-19 at the hospital entrance and again upon entry to the Maternal and Newborn Care
49
50 86 floor. Care providers wore full personal protective equipment at all times (e.g. universal
51
52 87 masking) as part of the hospital wide policy. A partner or support person could only enter once
53
54
55
56
57
58
59
60

COVID-19 and perinatal IPV

1
2
3 88 (i.e., no in and out privileges) after screening negative for COVID-19. Partners were not able to
4
5 89 attend caesarean births in the operating room. After birth, patients were not allowed to leave their
6
7 90 hospital room for any reason and no additional children or family members were allowed to visit.
8
9
10 91 For infants admitted to the Neonatal Intensive Care Unit (NICU), only one parent could be
11
12 92 present at a time.
13
14
15 93

Study design and recruitment

16
17 94
18
19 95 This is a cross-sectional survey of patients who gave birth at The Ottawa Hospital. Patients were
20
21 96 identified through the hospital birth records and contacted for a one-time survey if they met the
22
23 97 following inclusion criteria: had given birth after 17th March 2020, >20 days post-partum, 16
24
25 98 years of age or older, and consented to the hospital's Permission to Contact Program. Patients
26
27 99 were excluded if their pregnancy resulted in a still birth or neonatal death and were not
28
29
30
31 100 contacted. We chose 20 days post-partum as the cut-off to allow for at least 20 days to pass
32
33 101 where post-partum IPV could occur. To improve response rate, eligible patients were contacted
34
35 102 by phone and after obtaining verbal informed consent, a link to the online survey was sent to a
36
37 103 private email address. This allowed for private completion of the survey on a personal computer
38
39 104 or device. The survey took 10 minutes to complete. All participants were provided with links to
40
41 105 community resources for IPV, maternal support, or encouraged to contact the hospital for
42
43 106 referrals.
44
45
46
47 107

Patient and Public Involvement

48
49 108
50
51 109 The survey and all study materials were developed in collaboration with a Patient Partner
52
53 110 (O'Hare-Gordon), who was admitted to hospital during the COVID-19 pandemic and unable to
54
55
56
57
58
59
60

COVID-19 and perinatal IPV

1
2
3 111 see her partner and children for 5 weeks (22nd April to 27th May, 2020). She gave birth to pre-
4
5 112 term twins who were admitted to the Neonatal Intensive Care Unit (NICU) for 19 days.⁴¹ The
6
7 113 Patient Partner was not involved in recruitment. Participants will not be directly contacted with
8
9 114 the results of the study because of the sensitive nature of the project, however, public
10
11 115 dissemination of the findings are available through the institutional online platforms.
12
13
14
15 116

Outcomes

16
17 117
18
19 118 Perinatal IPV was measured by two scales from the World Health Organization multi-country
20
21 119 study on domestic violence.⁴² Scale One, comprised of eight questions, measures different forms
22
23 120 of regular controlling behaviour exhibited by the partner (e.g., insist on knowing where you are
24
25 121 at all times, try to keep you from seeing your friends, are often suspicious that you are unfaithful
26
27 122 etc.). Scale Two, measures act-based forms of IPV including emotional abuse (i.e., insulting,
28
29 123 belittling, intimidating, threatening to hurt someone you care about), physical abuse (i.e.,
30
31 124 slapped, pushed, hit, strangled, threatened with a weapon), and sexual abuse (i.e., forced to have
32
33 125 unwanted sexual intercourse, forced to have other unwanted sexual activities, forced to engage in
34
35 126 unwanted sexual activities they considered degrading or humiliating). The act-based forms of
36
37 127 perinatal IPV were asked for each perinatal time periods: 12 months before pregnancy, during
38
39 128 pregnancy, and post-partum. A composite outcome of any perinatal IPV was defined as
40
41 129 experiencing any regular controlling behaviour (Scale One) or any act-based forms of IPV (Scale
42
43 130 Two) during the perinatal period.
44
45
46
47
48
49 131

Covariables

COVID-19 and perinatal IPV

1
2
3 133 Demographic characteristics included age of mother (in years) and age of infant (in days) at the
4
5 134 time of the survey. The following maternal ethnicities are presented: White, Asian (including
6
7 135 South, South-East, East), Middle Eastern, Black, and Another Person of Colour (POC)).⁴³
8
9
10 136 Participants were asked if they were born in Canada or had immigrated from another country.
11
12 137 Participants identified any languages they feel comfortable speaking (i.e. English, French, or
13
14 138 another language). Marital status compared those who were married/common law versus
15
16 139 single/another status. Education level was measured as completing a college diploma or
17
18 140 undergraduate university degree or higher. Participants reported if they owned their dwelling
19
20 141 (versus rented) and their combined household income (before taxes), which was dichotomized as
21
22 142 either at or below the median total household income for the Ottawa region (119 440 CAD) as
23
24 143 determined by the Canadian Census.⁴⁴
25
26
27
28 144
29
30
31 145 COVID-19 related household stress was measured by loss of income due to COVID-19 protocols
32
33 146 (i.e. permanent job loss, temporarily laid off, or reduced hours) or if their partners were essential
34
35 147 workers, defined as those who were required to continue working during lockdown to maintain
36
37 148 the city infrastructure. Participants were asked if their partner had increased substance use since
38
39 149 COVID-19 began (i.e. alcohol, cannabis, tobacco, another substance). Changes to childcare were
40
41 150 measured as children stopped going to school or daycare, no changes to childcare, or no children.
42
43
44
45 151
46
47 152 Maternal experiences of COVID-19-related isolation included not being able to have a baby
48
49 153 shower (or other planned celebration), a family member could not come and stay with them as
50
51 154 planned, friends and family could not visit the new infant, or they missed out on community
52
53
54 155 resources (e.g. mom-baby groups, breastfeeding support groups, play dates).
55
56
57
58
59
60

COVID-19 and perinatal IPV

1
2
3 156
4
5 157 Measures of maternal mental health include pre-existing anxiety, pre-existing depression,
6
7 158 defined as receiving any counseling or treatment for anxiety or depression. Postpartum
8
9 159 depression was measured using the Edinburgh Postnatal Depression Scale (EPDS). The EPDS is
10
11 160 the most reliable and widely used screening tool for postpartum depression. The 10-item scale
12
13 161 ranges from 0 to 30 and a score of 13 or greater on the EPDS indicates a high likelihood of
14
15 162 depression and further assessment/management is needed. The score was presented continuously
16
17 163 and dichotomized at 13 or greater to indicate post-partum depression. If a participant scored
18
19 164 greater than 13 or indicated risk of suicidality (item 10), the Principal Investigator (DE,
20
21 165 Obstetrician) was notified within 24 hours of survey completion for a chart review and clinical
22
23 166 follow-up.
24
25
26
27
28
29
30

31 168 Participants reported on their in-hospital care experience including if they had to wear a mask
32
33 169 during delivery and if they were alone without a support person for the whole admission
34
35 170 (including early labour, active labour/delivery, and post-partum). Participants were asked if they
36
37 171 had any post-partum visit to an emergency department for mother or infant.
38
39
40
41
42
43

40 172
41
42 173
43
44 174 *Analyses*

45
46 175 All analyses were conducted using SAS 9.4.⁴⁵ In accordance with privacy guidelines, all cell
47
48 176 sizes <5 were suppressed to ensure non-identification. The characteristics of the sample were
49
50 177 summarized using descriptive statistics include frequencies and percentages for categorical
51
52 178 variables. Continuous variables were summarized using median and interquartile range (IQR),
53
54
55
56
57
58
59
60

COVID-19 and perinatal IPV

1
2
3 179 which are more robust measures and less sensitive to outliers. The characteristics of the sample
4
5 180 were compared between those who had experienced perinatal IPV versus those who had not by
6
7 181 calculating Chi-square tests for categorical variables and Wilcoxon ranked sum test for
8
9
10 182 continuous variables.

11
12 183

13
14 184 Log binomial regression models were calculated to investigate the association between five pre-
15
16 185 specified risk factors and perinatal IPV using unadjusted Risk Ratios (RR) and 95% confidence
17
18 186 intervals (CI). The risk factors were selected to capture individual, interpersonal and household
19
20 187 level factors that influence risk of violence including: maternal age, EPDS, parity, increases in
21
22 188 partners substance use, and household income below the municipal median. All covariables of
23
24 189 interest were included in the multivariable model and presented using adjusted RR and 95% CI.

25
26 190

27
28
29
30 191 Seven participants had at least one missing EPDS component. To compute the EPDS score we
31
32 192 imputed missing components with the mean of the participant's non-missing components. In the
33
34 193 multivariable model, missing data for household income was imputed by multiple imputation
35
36 194 using chained equations and models were averaged across 10 imputed datasets.⁴⁶

37
38 195

39
40
41 196 To evaluate the robustness of the analyses, we conducted a sensitivity analysis to remove
42
43 197 participants from the sample who reported pre-pregnancy act-based forms of IPV alone (i.e. no
44
45 198 controlling behaviours, no pregnancy or post-partum act-based forms of IPV) to assess concerns
46
47 199 of perinatal IPV that occurred before COVID-19 began.

48
49 20050
51
52
53 201 *Ethics*

COVID-19 and perinatal IPV

202 This study was approved by the Ottawa Health Sciences Network Research Ethics Board
203 (Protocol number: 20170390-01H).

204

205

Results

207 Between March 17th and June 16th, 1568 individuals gave birth at The Ottawa Hospital. Of those,
208 613 agreed to be contacted for research, 572 had valid phone numbers and were contacted, 302
209 consented to the study, and 261 started the survey, for a response rate of 42.58%. After excluding
210 those who did not finish the survey, the final analytical sample was of 216 participants. No
211 participants in the study reported current or previous COVID-19 infection.

212

213 There were 52 (24.07%) participants who reported perinatal IPV. In total, 37 (17.13%) reported
214 regular controlling behaviours from their partners, 24 (11.11%) reported act-based forms of IPV,
215 and 9 (4.17%) reported both (Table 1). The most common forms of regular controlling
216 behaviours from partners were that they ‘insist on knowing where you are at all times’ (8.33%),
217 ‘try to keep you from seeing your friends’ (5.58%) and ‘get angry if you speak with another man
218 or person they would feel jealous of’ (4.65%) (Figure 1, Appendix 1 for data tables)

219

220 Figure 2 displays the frequency of act-based forms of perinatal IPV experienced by participants
221 during each window of the perinatal period. In total, 13 (6.05%) experienced any form of IPV
222 during the 12 months prior to pregnancy, 11 (5.12%) during pregnancy, and 15 (6.98%) during
223 post-partum. The most common form of IPV reported by participants across all time periods was

COVID-19 and perinatal IPV

224 emotional abuse (10.23%). Sexual abuse was reported by 2.33% of participants, and <5 reported
225 physical abuse (see Appendix 2 for data tables).

226
227 The demographic characteristics of the sample are presented in Table 2. The maternal median
228 age was 33 years (IQR:30-36) and the infant median age at the time of the survey was 76 days
229 (IQR:66-90). The sample was diverse with 147 (68.06%) identifying as White, 31 (14.35%)
230 South/South-East or East Asian, 18 (8.33%) Middle Eastern, 17 (7.87%) Black, and 25 (11.57%)
231 identifying with another race or ethnic group. There were 151 (69.91%) participants who owned
232 their homes and 80 (37.04%) had household incomes below the municipal median.

233
234 Owing to COVID-19 restrictions, 64 (29.63%) reported household income loss and 55 (25.46%)
235 reported their partner was an essential worker who continued to work on the front line. There
236 were 45 (20.83%) participants who reported that their partner had increased substance use since
237 COVID-19 began. Regarding maternal mental health, 43 (19.91%) had pre-existing anxiety and
238 29 (13.43%) had pre-existing depression. There were 64 (29.63%) participants flagged for post-
239 partum depression through the EPDS.

240
241 The bivariable and multivariable log-binomial regression models are presented in Table 3. At the
242 bivariable level, household income below the municipal median (RR: 3.66, 95% CI:2.07-6.48) was
243 significantly associated with perinatal IPV and EPDS score (RR:1.04, 1.00-1.10) was marginally
244 associated. In the multivariable models, household income below the municipal median (aRR:
245 3.24, 95% CI: 1.87-5.59) was the strongest risk factor for any IPV and EPDS was marginally
246 associated (aRR: 1.03, 95% CI: 1.00-1.07). There was no independent association between

COVID-19 and perinatal IPV

247 maternal age (aRR: 0.99, 95% CI: 0.94-1.04), nulliparity (aRR: 1.18, 95% CI: 0.71-1.97), or
248 partner substance use increase (aRR: 0.73, 95% CI: 0.42-1.25) with IPV.

249
250 In sensitivity analyses, 5 individuals were identified who reported pre-pregnancy act-based forms
251 of perinatal IPV alone, when removed from the sample, the estimates remained the same. The
252 bivariable and multivariable results are available in Appendix 3.

253

254

Discussion

256 In our study sample, almost a quarter (24.07%) of the participants who gave birth during the
257 COVID-19 pandemic reported some form of perinatal IPV, including regular controlling
258 behaviours and act-based forms of IPV. Emotional abuse was the most common form of act-
259 based perinatal IPV, however, cases of sexual and physical abuse were also identified.

260 Household income was the strongest risk factor associated with perinatal IPV, and surprisingly,
261 many hypothesized risk factors (e.g., mental health, increased partner substance use etc.) were
262 not significantly associated with perinatal IPV in this sample.

263

264 A strength of this study is the detailed breakdown of the different forms, timing and frequency of
265 perinatal IPV, including revictimization that happened in multiple perinatal time periods.⁴⁷ The
266 estimated prevalence of perinatal IPV in this study is higher than previous studies of the perinatal
267 population (estimated to be an average of 3-9%) and online surveys investigating violence during
268 the COVID-19 pandemic (estimated between 10-17%).^{27,48} This may be influenced by the broad
269 definition of perinatal IPV that we used (i.e. two scales from the World Health Organization

COVID-19 and perinatal IPV

1
2
3 270 multi-country study on domestic violence), that capture more forms of perinatal IPV compared to
4
5 271 other scales.^{47,49-54} We chose an online survey as the method of administration, as online surveys
6
7
8 272 have been shown to have higher rates of disclosure compared to face-to-face, paper, or
9
10 273 voice/telephone.⁴⁹ Additionally, perinatal IPV included an observation window that included pre-
11
12 274 pregnancy IPV that occurred before the COVID-19 pandemic began.
13
14

275

16
17 276 In this analysis, the factor most strongly associated with perinatal IPV was socio-economic
18
19 277 status, contributing to over three times the risk of IPV. The association between income and
20
21 278 violence is well-established in the literature.⁵⁵ Consistent with findings from national
22
23 279 representative Canadian surveys,⁵⁶ almost 30% of participants reported household income loss
24
25 280 because of COVID-19 protocols, and 25% reported that their partners were essential workers,
26
27 281 but of interest, both of these factors were not significantly different by perinatal IPV status. This
28
29 282 finding may be highlighting that the sustained stress of lower socio-economic status poses a
30
31 283 greater risk for perinatal IPV than the potential short-term effects of COVID-19 related changes
32
33 284 in financial stability.
34
35
36
37

285

38
39 286 In the wake of COVID-19, attention has been drawn to the responsibility of health care
40
41 287 practitioner's for screening for and addressing IPV, including investigating circumstances around
42
43 288 injuries.⁵⁷ Within the obstetrical sphere, several commentaries have been written advocating for
44
45 289 integrating IPV assessments into ambulatory gynecologic care, post-partum recovery, mental
46
47 290 health, and reproductive life planning.⁵⁸⁻⁶¹ Systematic reviews and meta-analyses have identified
48
49 291 that strongest socio-demographic factors associated with elevated risk of perinatal IPV include
50
51 292 younger maternal age, single relationship status, visible minority status, lower socio-economic
52
53
54
55
56
57
58
59
60

COVID-19 and perinatal IPV

1
2
3 293 status, and substance use.^{59,62} Of interest within this study, several of the typical risk factors for
4
5 294 IPV were not significantly different by perinatal IPV status. This lends support for the
6
7
8 295 importance of universal IPV screening as risk factor-based screening may miss cases.
9

10 296
11
12 297 Despite the general pervasiveness of IPV and the increased risks posed by the COVID-19
13
14 298 pandemic, many health care providers are not well equipped to screen for violence or to take
15
16 299 action if IPV is identified.^{63,64} If children are in a home affected by violence there are legal
17
18 300 requirements to contact Children's Aid as part of due diligence.⁶⁵ However, there are no such
19
20 301 requirements for IPV, reinforcing a systemic barrier to violence prevention and care. During the
21
22 302 pandemic period many services have introduced modifications to services, including closure of
23
24 303 physical offices, which has limited access to interventionable options.¹⁵ However, obstetrical
25
26 304 departments are one of the few services that have continued to see patients in person. Pregnancy
27
28 305 and the postpartum period is a window of opportunity to identify and support people
29
30 306 experiencing violence who may have lost contact with other community services.
31
32
33
34
35
36
37

308 Limitations

38
39
40 309 We do not have information on those who did not consent to participate, which may introduce
41
42 310 self-selection bias, non-response bias or residual confounding, all factors that may explain why
43
44 311 several hypothesized risk factors were not significantly associated with perinatal IPV. All
45
46 312 measures of IPV were self-reported and may underestimate the prevalence of IPV within this
47
48 313 sample, however, the survey captured regular controlling behaviours that may not be perceived
49
50 314 as abusive in addition to act-based forms of emotional abuse (e.g., insulting, scaring, belittling
51
52
53 315 etc.), physical abuse (e.g. hitting, slapping, pushing), or sexual abuse (e.g., forced sexual
54
55
56
57
58
59
60

COVID-19 and perinatal IPV

1
2
3 316 activity). While 94.4% were married/common law, we do not have information on the length of
4
5 317 the relationship or if the participant had the same partner throughout the perinatal period. We did
6
7
8 318 not have a comparison group of participants prior to COVID-19 and are unable to estimate the
9
10 319 change in prevalence of perinatal IPV attributable to the increased stress of the COVID-19
11
12 320 pandemic. Additionally, this study was unable to evaluate associations between IPV and clinical
13
14
15 321 outcomes as we did not have information on maternal or newborn outcomes.
16
17 322

Conclusion

19 323
20
21 324 Almost a quarter of this obstetrical study population reported some form of perinatal IPV,
22
23 325 including IPV experienced pre-pregnancy, during pregnancy and post-partum. Owing to
24
25
26 326 COVID-19 lock-down measures, many participants reported household income loss, changes to
27
28 327 childcare, and increased isolation during pregnancy and post-partum; however, it was the strong
29
30 328 social determinant of income that was most strongly associated with IPV. As the COVID-19
31
32 329 pandemic evolves, it is critical to prioritize the health and safety of the perinatal population in
33
34
35 330 public health planning to ensure that households are fully supported and risks are mitigated.
36
37

38 331
39 332
40 333
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

*COVID-19 and perinatal IPV***334 Declarations****335 Ethical approval**

336 This study was approved by the Ottawa Health Sciences Network Research Ethics Board
337 (Protocol number: 20170390-01H). All participants provided informed verbal consent. All
338 methods were performed in accordance with standard ethical guidelines and regulations
339 (Declaration of Helsinki)

341 Consent for publication

342 Not applicable

344 Availability of data and materials

345 The datasets generated and analyzed during the current study are not publicly available due to
346 The Ottawa Hospital privacy protocols, but with a data sharing agreement, de-identified data, the
347 data dictionary, and ethics protocol are available from the corresponding author

349 Competing interests

350 All authors declare no conflicts of interest

352 Funding

353 The Ottawa Hospital Academic Medical Organization (TOHAMO): TOH-20-005

355 Author Contributions:

356 KM, KD, RT, CB, OF, AH, RRW, KS, DE conceived and designed the study. KS, MW, DE
357 provided clinical expertise and content. RT conducted the statistical analyses and KM, DF, YG,
358 MM, DC, SW provided methodological and analytic expertise. CB, OF, KD collected the data.
359 MOG is the patient partner. All authors critically reviewed the manuscript and approved the final
360 version. KM and DE have primary responsibility for the final content.

362 Acknowledgements

363 We would like to acknowledge all the participants who took the time to respond to this survey.
364 We thank Drs Jasmine Gandhi and Mark Kaluzienski for support developing the perinatal mental
365 health response study protocols.

COVID-19 and perinatal IPV

1
2
3 368 **Figure 1. Different forms of regular controlling behaviour from partner during COVID-19**
4 369 **(n=216)**

5 370
6 371 *Note: Measured using items from the World Health Organization Multi-Country Study on
7 372 Domestic Violence

8 373

9 374

10 375

11 376 **Figure 2. Forms and timing of act-based perinatal IPV (n=216)**

12 377

13 378 *Note Participants can report multiple forms of IPV. Cases of physical and sexual abuse were
14 379 identified, but suppressed because of small cell sizes

15 380

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

COVID-19 and perinatal IPV

381 **References**

- 382
- 383 1. Chandan JS, Taylor J, Bradbury-Jones C, Nirantharakumar K, Kane E, Bandyopadhyay S.
 384 COVID-19: A Public Health Approach to Manage Domestic Violence is Needed. *Lancet*
 385 *Public Heal.* 2020;2667(20):30112. doi:10.1016/S2468-2667(20)30112-2
- 386 2. de Girolamo G, Cerveri G, Clerici M, et al. Mental Health in the Coronavirus Disease
 387 2019 Emergency-The Italian Response. *JAMA Psychiatry.* 2020:2019-2021.
 388 doi:10.1001/jamapsychiatry.2020.1276
- 389 3. Mazza M, Marano G, Lai C, Janiri L, Sani G. Danger in danger: Interpersonal violence
 390 during COVID-19 quarantine. *Psychiatry Res.* 2020;289.
 391 doi:10.1016/j.psychres.2020.113046
- 392 4. Roesch E. Violence against women during Covid-19 pandemic restrictions. *Br Med J.*
 393 2020. doi:10.1136/bmj.m1712
- 394 5. Galea S, Merchant RM, Lurie N. The mental health consequences of COVID-19 and
 395 Physical distancing: The need for prevention and early intervention. *JAMA Intern Med.*
 396 2020;28(8):E1-2. doi:10.1002/da.20838
- 397 6. Breiding MJ, Basile KC, Smith SG, Black MC, Mahendra R. Intimate Partner Violence
 398 Surveillance: Uniform Definitions and Recommended Data Elements. *Natl Cent Inj Prev*
 399 *Control Centers Dis Control Prev.* 2015;36:706-707. doi:10.1136/bmj.328.7440.595
- 400 7. UN Women. *Policy Brief: The Impact of Covid-19 on Women.*; 2020.
 401 [https://www.unwomen.org/-](https://www.unwomen.org/-/media/headquarters/attachments/sections/library/publications/2020/policy-brief-the-impact-of-covid-19-on-women-en.pdf?la=en&vs=5029)
 402 [/media/headquarters/attachments/sections/library/publications/2020/policy-brief-the-](https://www.unwomen.org/-/media/headquarters/attachments/sections/library/publications/2020/policy-brief-the-impact-of-covid-19-on-women-en.pdf?la=en&vs=5029)
 403 [impact-of-covid-19-on-women-en.pdf?la=en&vs=5029.](https://www.unwomen.org/-/media/headquarters/attachments/sections/library/publications/2020/policy-brief-the-impact-of-covid-19-on-women-en.pdf?la=en&vs=5029)
- 404 8. Usher K, Bhullar N, Durkin J, Gyamfi N, Jackson D. Family Violence and COVID-19:
 405 increased vulnerability and reduced options for support. *Int J Ment Health Nurs.* 2020.
 406 doi:10.1111/inm.12735
- 407 9. Van Gelder N, Peterman A, Potts A, et al. COVID-19: Reducing the risk of infection
 408 might increase the risk of intimate partner violence. *EClinicalMedicine.* 2020;21:100348.
 409 doi:10.1016/j.eclinm.2020.100348
- 410 10. Violence Against Women Learning Network. *COVID-19 & Gender-Based Violence in*
 411 *Canada : Key Issues and Recommendations.* London, Ontario; 2020.
- 412 11. World Health Organization. *Global Status Report on Violence Prevention.*; 2014.
 413 doi:10.1007/s13398-014-0173-7.2
- 414 12. Hahn C, Gilmore A, Aguayo R, Rheingold A. Perinatal Intimate Partner Violence. *Obstet*
 415 *Gynecol Clin North Am.* 2018;45(3):535-547. doi:10.1016/j.physbeh.2017.03.040
- 416 13. Solomon MD, McNulty EJ, Rana JS, et al. The Covid-19 Pandemic and the Incidence of
 417 Acute Myocardial Infarction. *N Engl J Med.* 2020;e-pub ahea:10-12.
- 418 14. Frankfurter C, Buchan TA, Kobulnik J, et al. Reduced Rate of Hospital Presentations for
 419 Heart Failure During the COVID-19 Pandemic in Toronto, Canada. *Can J Cardiol.*
 420 2020:1-5. doi:10.1016/j.cjca.2020.07.006
- 421 15. Muldoon KA, Denize KM, Talarico R, et al. COVID-19 pandemic and violence : rising
 422 risks and decreasing urgent care-seeking for sexual assault and domestic violence
 423 survivors. *BMC Med.* 2021:1-9.
- 424 16. Olding J, Zisman S, Olding C, Fan K. Penetrating trauma during a global pandemic:
 425 Changing patterns in interpersonal violence, self-harm and domestic violence in the
 426 Covid-19 outbreak. *Surgeon.* 2020;(xxxx). doi:10.1016/j.surge.2020.07.004

COVID-19 and perinatal IPV

- 1
2
3 427 17. Morris D, Rogers M, Kissmer N, Du A, Dufourq N. Impact of lockdown measures
4 428 implemented during the COVID-19 pandemic on the burden of trauma presentation to a
5 429 regional emergency department in Kwa-Zulu Natal, South Africa. *African J Emerg Med.*
6 430 2020;in press(January).
- 8 431 18. Garstang J, Debelle G, Anand I, et al. Effect of COVID-19 lockdown on child protection
9 432 medical assessments: A retrospective observational study in Birmingham, UK. *BMJ Open.*
10 433 2020;10(9):1-6. doi:10.1136/bmjopen-2020-042867
- 12 434 19. Barbara G, Facchin F, Micci L, et al. COVID-19, Lockdown, and Intimate Partner
13 435 Violence: Some Data from an Italian Service and Suggestions for Future Approaches. *J*
14 436 *Women's Heal.* 2020;29(10):1239-1242. doi:10.1089/jwh.2020.8590
- 16 437 20. Piquero AR, Riddell JR, Bishopp SA, Narvey C, Reid JA, Piquero NL. Staying Home,
17 438 Staying Safe? A Short-Term Analysis of COVID-19 on Dallas Domestic Violence. *Am J*
18 439 *Crim Justice.* 2020. doi:10.1007/s12103-020-09531-7
- 20 440 21. Leslie E, Wilson R. Sheltering in place and domestic violence: Evidence from calls for
21 441 service during COVID-19. *J Public Econ.* 2020;189:104241.
22 442 doi:10.1016/j.jpubeco.2020.104241
- 24 443 22. Sutherland M, McKenney M, Elkbuli A. Gun violence during COVID-19 pandemic:
25 444 Paradoxical trends in New York City, Chicago, Los Angeles and Baltimore. *Am J Emerg*
26 445 *Med.* 2020;(xxxx):5-6. doi:10.1016/j.ajem.2020.05.006
- 28 446 23. Statistics Canada. *Police-Reported Crime Incidents down during the Early Months of the*
29 447 *Pandemic , While Domestic Disturbance Calls Increase.* Ottawa; 2020.
- 31 448 24. Payne JL, Morgan A, Piquero AR. COVID-19 and social distancing measures in
32 449 Queensland, Australia, are associated with short-term decreases in recorded violent crime.
33 450 *J Exp Criminol.* 2020. doi:10.1007/s11292-020-09441-y
- 35 451 25. Hodgkinson T, Andresen MA. Show me a man or a woman alone and I ' ll show you a
36 452 saint : Changes in the frequency of criminal incidents during the COVID-19 pandemic. *J*
37 453 *Crim Justice.* 2020;(January).
- 39 454 26. Mohler G, Bertozzi AL, Carter J, et al. Impact of social distancing during COVID-19
40 455 pandemic on crime in Los Angeles and Indianapolis. *J Crim Justice.* 2020;68(March).
41 456 doi:10.1016/j.jcrimjus.2020.101692
- 43 457 27. Lindberg L, VandeVusse D, Mueller A, Kirstein J, Mariell. *Early Impacts of the COVID-*
44 458 *19 Pandemic: Findings from the 2020 Guttmacher Survey of Reproductive Health*
45 459 *Experiences.* New York; 2020. www.guttmacher.org.
- 47 460 28. Jetelina KK, Knell G, Molsberry RJ. Changes in intimate partner violence during the early
48 461 stages of the COVID-19 pandemic in the USA. *Inj Prev.* 2020;0:1-5.
49 462 doi:10.1136/injuryprev-2020-043831
- 51 463 29. Id SE, Jenkins M, Gendall P, et al. Psychological distress, anxiety, family violence,
52 464 suicidality, and wellbeing in New Zealand during the COVID-19 lockdown : A cross-
53 465 sectional study. *PLoS One.* 2020;15(11):1-19. doi:10.1371/journal.pone.0241658
- 55 466 30. Abou Ghayda R, Li H, Lee KH, et al. COVID-19 and Adverse Pregnancy Outcome: A
56 467 Systematic Review of 104 Cases. *J Clin Med.* 2020;9(11):3441. doi:10.3390/jcm9113441
- 58 468 31. Di Mascio D, Khalil A, Saccone G, et al. Outcomes of coronavirus spectrum infections
59 469 (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis.
60 470 *Am J Obstet Gynecol.* 2020;(January).
- 62 471 32. Novoa RH, Quintana W, Llancarí P, Urbina-Quispe K, Guevara-Ríos E, Ventura W.
63 472 Maternal clinical characteristics and perinatal outcomes among pregnant women with

COVID-19 and perinatal IPV

- 1
2
3 473 coronavirus disease 2019. A systematic review. *Travel Med Infect Dis.* 2021;39(June
4 474 2020):101919. doi:10.1016/j.tmaid.2020.101919
5 475 33. Vardhelli V, Pandita A, Pillai A, Badatya SK. Perinatal COVID-19: review of current
6 476 evidence and practical approach towards prevention and management. *Eur J Pediatr.*
7 477 2020. doi:10.1007/s00431-020-03866-3
8 478 34. Zaigham M, Andersson O. Maternal and perinatal outcomes with COVID-19: A
9 479 systematic review of 108 pregnancies. *Acta Obstet Gynecol Scand.* 2020;99(7):823-829.
10 480 doi:10.1111/aogs.13867
11 481 35. Yee J, Kim W, Han JM, et al. Clinical manifestations and perinatal outcomes of pregnant
12 482 women with COVID-19: a systematic review and meta-analysis. *Sci Rep.* 2020;10(1):1-7.
13 483 doi:10.1038/s41598-020-75096-4
14 484 36. Di Toro F, Gjoka M, Di Lorenzo G, et al. Impact of COVID-19 on maternal and neonatal
15 485 outcomes: a systematic review and meta-analysis. *Clin Microbiol Infect.* 2020;(xxxx).
16 486 doi:10.1016/j.cmi.2020.10.007
17 487 37. Zambrano LD, Ellington S, Strid P, et al. Update: Characteristics of Symptomatic Women
18 488 of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy
19 489 Status — United States, January 22–October 3, 2020. *MMWR Morb Mortal Wkly Rep.*
20 490 2020;69(44):1641-1647. doi:10.15585/mmwr.mm6944e3
21 491 38. Hessami K, Romanelli C, Chiurazzi M, Cozzolino M. COVID-19 pandemic and maternal
22 492 mental health: a systematic review and meta-analysis. *J Matern Neonatal Med.* 2020.
23 493 doi:10.1080/14767058.2020.1843155
24 494 39. Preis H, Mahaffey B, Heiselman C, Lobel M. Pandemic-related pregnancy stress and
25 495 anxiety among women pregnant during the coronavirus disease 2019 pandemic. *Am J*
26 496 *Obstet Gynecol MFM.* 2020;2(3):100155. doi:10.1016/j.ajogmf.2020.100155
27 497 40. Government of Canada. Coronavirus disease 2019 (COVID-19): Epidemiology update.
28 498 41. The Ottawa Hospital. High-risk twin pregnancy during COVID-19 pandemic.
29 499 42. Garcia-Moreno C, Jansen HAFM, Ellsberg M, Heise L, Watts C. WHO Multi-Country
30 500 Study on Women's Health and Domestic Violence Against Women: Report on the First
31 501 Results. *World Heal Organ.* 2005:55-89.
32 502 43. Ottawa Public Health. Socio-demographic data and population projects. General
33 503 Population Health.
34 504 44. Statistics Canada. Distribution of total income by census family type and age of older
35 505 partner, parent, or individual. <https://www150.statcan.gc.ca/n1/en/catalogue/1110001201>.
36 506 Published 2017. Accessed December 18, 2020.
37 507 45. SAS Institute Inc. SAS Institute Inc. 2017.
38 508 46. Azur MJ, Stuart EA, Frangakis C, Leaf PJ. Multiple imputation by chained equation:
39 509 What is it and how does it work. *Int J Methods Psychiatr Res.* 2011;20(1):40-49.
40 510 doi:10.1002/mpr
41 511 47. Rodrigues T, Rocha L, Barros H. Physical abuse during pregnancy and preterm delivery.
42 512 *Am J Obstet Gynecol.* 2008;198(2):171.e1-171.e6. doi:10.1016/j.ajog.2007.05.015
43 513 48. Hui DSC, Chan PKS. Severe acute respiratory syndrome and coronavirus. *Infect Dis Clin*
44 514 *North Am.* 2010;24(3):619-638. doi:10.1016/j.idc.2010.04.009
45 515 49. Fraga S, Lucas R, Barros H. A comparison of methods to assess intimate partner abuse 1
46 516 year postpartum. *Ann Epidemiol.* 2014;24(5):404-406.
47 517 doi:10.1016/j.annepidem.2014.02.005
48 518 50. Macmillan HL, Wathen CN, Jamieson E, et al. Approaches to Screening for Intimate

COVID-19 and perinatal IPV

- 1
2
3 519 Partner Violence in Health Care Settings A Randomized Trial. *JAMA*. 2006;296(5):530-
4 520 536. <https://jamanetwork.com/>.
- 5 521 51. Taillieu TL, Brownridge DA, Tyler KA, Chan KL, Tiwari A, Santos SC. Pregnancy and
6 522 Intimate Partner Violence in Canada: a Comparison of Victims Who Were and Were Not
7 523 Abused During Pregnancy. *J Fam Violence*. 2016;31(5):567-579. doi:10.1007/s10896-
8 524 015-9789-4
- 9 525 52. Daoud N, Urquia ML, O'campo P, et al. Prevalence of Abuse and Violence Before,
10 526 During, and After Pregnancy in a National Sample of Canadian Women. *Am J Public*
11 527 *Health*. 2012;102(10):1893-1901. doi:10.2105/AJPH.2012
- 12 528 53. Graham-Kevan N, Archer J. Investigating Three Explanations of Women's Relationship
13 529 Aggression. *Psychol Women Q*. 2005:270-277.
- 14 530 54. McFarlane J, Parker B, Soeken K, Bullock L, McFarlane H. Assessing for Abuse During
15 531 Pregnancy: Severity and Frequency of Injuries and Associated Entry Into Prenatal Care.
16 532 *JAMA*. 1992;267(23). <https://jamanetwork.com/>.
- 17 533 55. Pastor-Moreno G, Ruiz-Pérez I, Henares-Montiel J, Petrova D. Intimate partner violence
18 534 during pregnancy and risk of fetal and neonatal death: a meta-analysis with socioeconomic
19 535 context indicators. *Am J Obstet Gynecol*. 2019;(February). doi:10.1016/j.ajog.2019.07.045
- 20 536 56. Statistics Canada. *Canadian Perspectives Survey Series 1 : Impacts of COVID-19.*; 2020.
21 537 [https://www150.statcan.gc.ca/n1/en/daily-quotidien/200408/dq200408c-](https://www150.statcan.gc.ca/n1/en/daily-quotidien/200408/dq200408c-eng.pdf?st=AhCEAktc)
22 538 [eng.pdf?st=AhCEAktc](https://www150.statcan.gc.ca/n1/en/daily-quotidien/200408/dq200408c-eng.pdf?st=AhCEAktc).
- 23 539 57. Bradley N., DiPasquale AM, Dillabough K, Schneider PS. Health care practitioners'
24 540 responsibility to address intimate partner violence related to the COVID-19 pandemic.
25 541 *Can Med Assoc J*. 2020;1-2. doi:10.1503/cmaj.200634
- 26 542 58. Cohen MA, Powell AM, Coleman JS, Keller JM, Livingston A, Anderson JR. Special
27 543 ambulatory gynecologic considerations in the era of coronavirus disease 2019 (COVID-
28 544 19) and implications for future practice. *Am J Obstet Gynecol*. 2020;223(3):372-378.
29 545 doi:10.1016/j.ajog.2020.06.006
- 30 546 59. Sadler M, Leiva G, Olza I. COVID-19 as a risk factor for obstetric violence. *Sex Reprod*
31 547 *Heal Matters*. 2020;28(1). doi:10.1080/26410397.2020.1785379
- 32 548 60. Choi K, Records K, Low LK, et al. Promotion of Maternal–Infant Mental Health and
33 549 Trauma-Informed Care During the Coronavirus Disease 2019 Pandemic. *J Obstet Gynecol*
34 550 *Neonatal Nurs*. 2020;(August):1-7. doi:10.1016/j.jogn.2020.07.004
- 35 551 61. Tang K, Gaoshan J, Ahonsi B. Sexual and reproductive health (SRH): a key issue in the
36 552 emergency response to the coronavirus disease (COVID- 19) outbreak. *Reprod Health*.
37 553 2020;17(59). doi:10.1186/s12978-020-0900-9
- 38 554 62. Costa D, Hatzidimitriadou E, Ioannidi-Kapolou E, et al. Male and female physical
39 555 intimate partner violence and socio-economic position: a cross-sectional international
40 556 multicentre study in Europe. *Public Health*. 2016;139:44-52.
41 557 doi:10.1016/j.puhe.2016.05.001
- 42 558 63. Rabin RF, Jennings JM, Campbell JC, Bair-Merritt MH. Intimate Partner Violence
43 559 Screening Tools. A Systematic Review. *Am J Prev Med*. 2009;36(5):439-445.e4.
44 560 doi:10.1016/j.amepre.2009.01.024
- 45 561 64. Doherty OL, Hegarty K, Ramsay J, Davidson L, Feder G, Taft A. Screening women for
46 562 intimate partner violence in healthcare settings (Review). *Cochrane Database Syst Rev*
47 563 *Screenin*. 2015;(7). doi:10.1002/14651858.CD007007.pub3.www.cochranelibrary.com
- 48 564 65. Government of Ontario. *Child, Youth and Family Services Act , 2017, Chapter 14*.
- 49
50
51
52
53
54
55
56
57
58
59
60

COVID-19 and perinatal IPV

565 Canada; 2017:1-166.

566

567

568

For peer review only

*COVID-19 and perinatal IPV*569 **Table 1. Different forms of perinatal violence and combinations**

570

Perinatal IPV measures	N=216 n(%)
Act-based forms of perinatal IPV or regular controlling behaviour	
Yes	52 (24.07)
No	164 (75.93)
Act-based forms of perinatal IPV	
Yes	24 (11.11)
No	192 (88.89)
Regular controlling behaviours	
Yes	37 (17.13)
No	179 (82.87)
Acts of perinatal IPV and regular controlling behaviour	
Yes	9 (4.17)
No	207 (95.83)
Frequency of act-based forms of perinatal IPV	
Single time period	13 (6.02)
Multiple time periods	11 (5.09)
No acts of perinatal IPV	192 (88.89)

571

572

COVID-19 and perinatal IPV

573 **Table 2. General characteristics of study participants who have given birth since the COVID-19**
 574 **pandemic began (n=216)**
 575

Variables	Perinatal IPV		Total N=216	p- values
	Yes (n=52)	No (164)		
Demographic characteristics				
Maternal Age in years (median, IQR)	32 (30-34)	33 (30-36)	33 (30-36)	0.089
Infant age in days at time of interview (median, IQR)	80 (67-89)	75 (65-90)	76 (66-90)	0.375
Month of Delivery in 2020				
March	11 (21.15)	28 (17.07)	39 (18.06)	0.800
April	21 (40.38)	61 (37.20)	82 (37.96)	
May	13 (25.00)	51 (31.10)	64 (29.63)	
June	7 (13.46)	24 (14.63)	31 (14.35)	
Nulliparous vs multiparous	32 (61.54)	86 (52.44)	118 (54.63)	0.251
Race or Ethnicity ¹				
White	31 (59.62)	116 (70.73)	147 (68.06)	0.134
Asian – South/East/South-East	9 (17.31)	22 (13.41)	31 (14.35)	0.485
Middle Eastern	8 (15.38)	10 (6.10)	18 (8.33)	0.035
Black	5 (9.62)	12 (7.32)	17 (7.87)	0.592
Another PoC group	9 (17.31)	16 (9.76)	25 (11.57)	0.138
Born in Canada vs immigrated	34 (65.38)	125 (76.22)	159 (73.61)	0.122
Marital status: Married/common law vs single/another status	48 (92.31)	156 (95.12)	204 (94.44)	0.440
Completed college diploma or under-graduate degree	44 (84.62)	144 (87.80)	188 (87.04)	0.551
Language(s) comfortable speaking¹				
Speaks English	51 (98.08)	161 (98.17)	212 (98.15)	0.965
Speaks French	19 (36.54)	55 (33.54)	74 (34.26)	0.691
Speaks another language	9 (17.31)	20 (12.20)	29 (13.43)	0.346
Income				
Dwelling owned vs rented	29 (55.77)	122 (74.39)	151 (69.91)	0.011
Combined household income below Ottawa median ²	34 (65.38)	46 (28.05)	80 (37.04)	<0.001
COVID-19 related household stress				
Any household income loss	19 (36.54)	45 (27.44)	64 (29.63)	0.211
Partner is essential worker	12 (23.08)	43 (26.22)	55 (25.46)	0.650
Partner substance use increased	12 (23.08)	33 (20.12)	45 (20.83)	0.648
Children's schedule				
Children stopped going to school or daycare	17 (32.69)	67 (40.85)	84 (38.89)	0.515
Children's schedule did not change	-	-	14 (6.48)	
No children	32 (61.54)	86 (52.44)	118 (54.63)	
Isolation due to COVID-19 restrictions				
No baby shower or planned celebration	29 (55.77)	70 (42.68)	99 (45.83)	0.099
Family member couldn't come to stay with me as planned	30 (57.69)	78 (47.56)	108 (50.00)	0.203
Friends and family could not visit my new baby	41 (78.85)	129 (78.66)	170 (78.70)	0.977
Missed out on community resources	46 (88.46)	137 (83.54)	183 (84.72)	0.390
Mental health				

COVID-19 and perinatal IPV

Pre-existing anxiety	13 (25.00)	30 (18.29)	43 (19.91)	0.291
Pre-existing depression	7 (13.46)	22 (13.41)	29 (13.43)	0.993
Post-partum depression (EPDS 13 cut-off)	20 (38.46)	44 (26.83)	64 (29.63)	0.109
EPDS Score (med, IQR)	10 (5-14)	8 (4-13)	8 (4-13)	0.130
Healthcare experiences				
Alone for all labour and delivery	-	-	16 (7.41)	0.928
Wear a mask during delivery	22 (42.31)	75 (45.73)	97 (44.91)	0.665
Any post-partum emergency department visit for mother or infant	11 (21.15)	31 (18.90)	42 (19.44)	0.721
Coping mechanisms				
Positive coping mechanisms ³	49 (94.23)	160 (97.56)	209 (96.76)	0.237
Negative coping mechanisms ⁴	38 (73.08)	101 (61.59)	139 (64.35)	0.132

Cell sizes ≤ 5 and are suppressed; p-values are calculated with Chi-square test for categorical variables and

Wilcoxon rank sum tests for continuous variables; IQR= interquartile range


1. Participants can pick multiple race/ethnic groups or languages
2. Missing data=24 cases
3. Positive coping mechanisms include: yoga, exercising, donating to charity, connecting with friends/family
4. Negative coping mechanism include: sleeping more or less; over/under eating, acting aggressively

*COVID-19 and perinatal IPV***Table 3. Bivariable and Multivariable log binomial regression models to assess factors associated with perinatal IPV (n=216)**

Co-Variables	RR (95% CI)	p-value	ARR (95% CI)	p-value
Maternal Age in years (median, IQR)	0.95 (0.90-1.00)	0.082	0.99 (0.94-1.04)	0.660
EPDS Score (continuous)	1.04 (1.00-1.10)	0.040	1.03 (1.00-1.07)	0.077
Nulliparous vs multiparous	1.33 (0.76-2.32)	0.319	1.18 (0.71-1.97)	0.529
Partner substance use increased	1.14 (0.60-2.17)	0.691	0.73 (0.42-1.25)	0.249
Household income below vs above Ottawa median ¹	3.66 (2.07-6.48)	<0.001	3.24 (1.87-5.59)	<0.001

1. Missing data for household income was imputed by multiple imputation using chained equations and models were averaged across 10 imputed datasets
2. Outcome is defined as any reported regular controlling behaviour or act-based perinatal IPV (emotional, physical, sexual)


Figure 1. Different forms of regular controlling behaviour from partner during COVID-19 (n=216)



*Note: Measured using items from the World Health Organization Multi-Country Study on Domestic Violence

Peer review only

Figure 2. Forms and timing of act-based forms of perinatal IPV (n=216)



Note: Participants can report multiple forms of IPV. Cases of physical and sexual abuse were identified, but suppressed because of small cell sizes

Appendix Tables perinatal IPV

Appendix 1. Data tables for figure 1

Forms of regular controlling behaviour	n(%)
Any controlling behaviour	37 (17.21)
Insist on knowing where you are at all times	18 (8.37)
Try to keep you from seeing your friends	12 (5.58)
Get angry if you speak with another man or a person they would be jealous of	10 (4.65)
Insist on coming to your healthcare appointments	9 (4.19)
Ignore you and/or treat you indifferently	9 (4.19)
Try to restrict you from connecting with your family	6 (2.79)
Are often suspicious that you are unfaithful	5 (2.33)
Expect you to ask their permission before seeking healthcare for yourself	-

- Cell suppressed because of small cell size

*Appendix Tables perinatal IPV***Appendix 2. Data tables for figure 2**

Perinatal IPV variables	n(%)
Any acts of perinatal IPV	37 (17.21)
12 months pre-pregnancy	13 (6.05)
During pregnancy	11 (5.12)
Post-partum	15 (6.98)
Emotional abuse	
12 months pre-pregnancy	11 (5.12)
During pregnancy	11 (5.12)
Post-partum	15 (6.98)
Any perinatal time period	22 (10.23)
Physical abuse	
12 months pre-pregnancy	-
During pregnancy	-
Post-partum	-
Any perinatal time period	-
Sexual abuse	
12 months pre-pregnancy	5 (2.33)
During pregnancy	-
Post-partum	-
Any perinatal time period	5 (2.33)
- Cell Cell suppressed because of small cell size	

Appendix Tables perinatal IPV

Appendix 3. Sensitivity analyses for bivariable and multivariable log binomial regression models to assess factors associated with perinatal IPV by removing 5 participants who indicated act-based pre-pregnancy IPV alone (n=211)¹

Co-Variables	RR (95% CI)	p-value	ARR (95% CI)	p-value
Maternal Age in years (median, IQR)	0.95 (0.90-1.01)	0.090	0.99 (0.94-1.05)	0.807
Nulliparous vs multiparous	1.56 (0.85-2.85)	0.151	0.71 (0.41-1.24)	0.230
Household income below vs above Ottawa median ²	3.47 (1.94-6.19)	<0.001	3.42 (1.89-6.19)	<0.001
EPDS Score (continuous)	1.03 (0.99-1.08)	0.169	1.03 (0.98-1.07)	0.279
Partner substance use increased	1.16 (0.59-2.28)	0.667	0.67 (0.38-1.16)	0.153

1. Sample restricted to participants who reported any controlling behaviours or perinatal IPV acts during pregnancy and post-partum. Five individuals were removed from this analysis who reported perinatal IPV acts during the pre-pregnancy period alone
2. Missing data for household income was imputed by multiple imputation using chained equations and models were averaged across 10 imputed datasets

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract Included: abstract The study is a cross-sectional study
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found Included: Abstract, methods and results section
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported Included: Introduction Section (p.4-6)
Objectives	3	State specific objectives, including any prespecified hypotheses Included: Introduction Section (p. 6)
Methods		
Study design	4	Present key elements of study design early in the paper Included: Methods –Study design and recruitment (p. 7-8)
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Included: Methods – Study setting and context, Study design and recruitment (p. 7-8)
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up na (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed na
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Included: Methods – Outcomes, Covariables (p.8-10)
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Included: Methods – Outcomes, Covariables (p.8-10)
Bias	9	Describe any efforts to address potential sources of bias Included: Methods Section – Study design and recruitment (p. 7-8), Analysis (p.11)
Study size	10	Explain how the study size was arrived at A sample size was not calculated because all eligible patients were contacted
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Included: Methods – Outcomes, Covariables (p.8-10), Analysis (p.11)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Statistical methods

12 (a) Describe all statistical methods, including those used to control for confounding

Included: Methods Section – Analysis (p.11)

(b) Describe any methods used to examine subgroups and interactions

Included: Methods Section – Analysis (p.11)

(c) Explain how missing data were addressed

Methods Section – Analysis (p.11)(d) *Cohort study*—If applicable, explain how loss to follow-up was addressed

Included: na

(e) Describe any sensitivity analyses

NA

Continued on next page

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed Included: The description of the study population is described in the Results Section. (p.12) (b) Give reasons for non-participation at each stage Included: Participation and response rate are described in the Results Section. (p.12) (c) Consider use of a flow diagram (Figure 1)
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Included: Results Section – (p 12-13) (b) Indicate number of participants with missing data for each variable of interest Missing data is foot-noted in each table (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount) Included: na
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time Included: na
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included Included: Results Section – (p 13-14), Table 2 (b) Report category boundaries when continuous variables were categorized Included: Results Section – (p 12), Table 1 (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18	Summarise key results with reference to study objectives Included: Discussion Section (p.14-17)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias Included: Discussion Section (p.16)
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence Included: Discussion Section (p.14-17)
Generalisability	21	Discuss the generalisability (external validity) of the study results Included: Discussion Section (p. 16)
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based Funding: The Ottawa Hospital Academic Medical Organization (TOHAMO): TOH-20-005

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

For peer review only